Pathway activity analysis of bulk and single-cell RNA-Seq data by Jenkins, David
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
Pathway activity analysis of bulk
and single-cell RNA-Seq data
https://hdl.handle.net/2144/34809
Boston University
BOSTON UNIVERSITY 
 
GRADUATE SCHOOL OF ARTS AND SCIENCES 
 
AND 
 
COLLEGE OF ENGINEERING 
 
 
 
 
Dissertation 
 
 
 
 
PATHWAY ACTIVITY ANALYSIS OF 
 
BULK AND SINGLE-CELL RNA-SEQ DATA 
 
 
 
 
by 
 
 
 
 
DAVID FOWLER JENKINS III 
 
Sc.B., Brown University, 2011 
M.S., Boston University, 2017 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2019  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2019 
 David Fowler Jenkins III 
 All rights reserved  
Approved by 
 
 
 
 
 
First Reader _________________________________________________________ 
 W. Evan Johnson, Ph.D. 
 Associate Professor of Medicine and Biostatistics 
 
 
Second Reader _________________________________________________________ 
 Joshua D. Campbell, Ph.D. 
 Assistant Professor of Medicine 
 
 
  iv 
DEDICATION 
 
 
 
 
To my grandparents 
Paul, Loretta, William, and Antoinette. 
  
  v 
ACKNOWLEDGMENTS 
My thesis work would not have been possible without a team of people helping 
me along the way, so I’d like to say thank you. First and foremost, to my advisor Evan, 
whose infectious enthusiasm I felt from the first day we met in 2014. I left every meeting 
with you inspired to work hard, and I won’t ever forget that, thank you. To my 
collaborators, particularly Andrea Bild, Moom Rahman, and Shelley MacNeil, I’m proud 
of the work we did together, thank you. To my fellow lab mates, especially Tyler, 
Supriya, Mani, Yuqing, and Jason, thanks for your positive feedback and support. To my 
thesis committee, Paola, Josh, Jen, and Masanao, thanks for your suggestions and 
flexibility, it was a pleasure to work with you. To the BU Bioinformatics program, 
particularly Caroline Lyman, Johanna Vasquez, and David King, you have been more 
than generous with your time and resources; we all really appreciate the work you do to 
make our graduate work go as smoothly as possible. To my friends, both old and new, for 
always being there to make me laugh or listen to me when I needed you, thank you. 
Finally, to my family, Dave, Caroline, Emma, Sam, Gram L, and Paula, I love you.  
  vi 
PATHWAY ACTIVITY ANALYSIS OF 
BULK AND SINGLE-CELL RNA-SEQ DATA 
DAVID FOWLER JENKINS III 
Boston University Graduate School of Arts and Sciences 
and College of Engineering, 2019 
Major Professor: W. Evan Johnson, Associate Professor of Medicine and Biostatistics 
 
ABSTRACT 
 Gene expression profiling can produce effective biomarkers that can provide 
additional information beyond other approaches for characterizing disease. While these 
approaches are typically performed on standard bulk RNA sequencing data, new methods 
for RNA sequencing of individual cells have allowed these approaches to be applied at 
the resolution of a single cell. As these methods enter the mainstream, there is an 
increased need for user-friendly software that allows researchers without experience in 
bioinformatics to apply these techniques. In this thesis, I have developed new, user-
friendly data resources and software tools to allow researchers to use gene expression 
signatures in their own datasets. Specifically, I created the Single Cell Toolkit, a user-
friendly and interactive toolkit for analyzing single-cell RNA sequencing data and used 
this toolkit to analyze the pathway activity levels in breast cancer cells before and after 
cancer therapy. Next, I created and validated a set of activated oncogenic growth factor 
receptor signatures in breast cancer, which revealed additional heterogeneity within 
public breast cancer cell line and patient sample RNA sequencing datasets. Finally, I 
created an R package for rapidly profiling TB samples using a set of 30 existing 
tuberculosis gene signatures. I applied this tool to look at pathway differences in a dataset 
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of tuberculosis treatment failure samples. Taken together, the results of these studies 
serve as a set of user-friendly software tools and data sets that allow researchers to 
rapidly and consistently apply pathway activity methods across RNA sequencing 
samples.  
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Chapter 1. Introduction 
Transcriptional Regulation and Disease 
 It is well established that cell signaling plays an important role in disease (Nahta, 
Hortobágyi & Esteva, 2003). The cell is a highly regulated and carefully controlled 
machine, with many signaling pathways working together to address the needs of each 
cell (Schlessinger, 2000). When these pathways are disrupted, there can be devastating 
effects. When attempting to quantify these changes in pathway activity there are several 
levels to probe. Alterations in DNA (DNA mutations) can cause changes in pathway 
activity, deactivating or activating a specific transcription factor, but redundancy in 
transcription factor pathways means that not every mutational event will have a strong, if 
any, effect (Spitz, Furlong, 2012). Further, many DNA mutations occur in positions in the 
genome that have no effect, so sifting through many mutations to identify the causal 
change is often difficult. An alternative approach is to quantify RNA expression. 
Messenger RNA (mRNA) is the transcriptional language that converts the instructions 
coded in DNA into protein products. By quantifying the level of RNA expression for 
each gene in a specific sample, a picture of the cellular activity of these genes can be 
identified. Differences in the levels of gene expression across samples can point to the 
causes of disease phenotypes or be used as a biomarker of a specific disease state. Often 
these biomarkers are not a single value, but a set of coordinately expressed genes that 
form a signature that can represent the activity of a cellular component, such as a 
pathway. By identifying biomarkers of disease, we can stratify patients into groups with 
similar cellular activity, which can often respond to disease treatments in similar ways 
(Groenendijk, Bernards, 2014, McCubrey et al., 2012). 
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Transcriptional Pathways in Cancer 
 In cancer, activating or inactivating mutations can disrupt the cell signaling 
cascades that control how cells grow, divide, and undergo apoptosis (McCubrey et al., 
2012). These changes in cell signaling networks have become an important part of the set 
of ‘hallmarks of cancer,’ causing cells to grow uncontrollably, form tumors, and 
metastasize (Hanahan, Weinberg, 2011). Cancer is one of the leading causes of death 
globally with an estimated 18.1 million new cases in 2018 (The International Agency for 
Research on Cancer, 2018). Fortunately, targeted cancer drugs to address specific 
abnormalities in cancer signaling pathways have been developed (Gustafson et al., 2010). 
These targeted drugs can inhibit certain signaling pathways driven by key oncogenic 
growth factor receptors, such as EGFR and HER2 (Nahta, Hortobágyi & Esteva, 2003). 
Importantly, by identifying the signaling cascade that is driving a specific tumor, drugs 
that target components of that pathway can be administered. The ultimate goal of 
pathway analysis in cancer is to identify a set of biomarkers that can precisely 
characterize the drivers of a specific tumor and identify the drugs that would best target 
the exact combination of aberrations in a specific patient’s tumor, an approach commonly 
known as personalized medicine. 
Tuberculosis 
 Tuberculosis (TB) infection is a leading cause of death worldwide (World Health 
Organization, 2016). The majority of patients infected with TB will not progress to active 
TB disease (World Health Organization, 2016). Of those that do get infected, some will 
fail their treatment. In TB, many gene signatures have been produced that can accurately 
predict the likelihood of TB progression or predict active TB disease (Zak et al., 2016, 
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Sambarey et al., 2017, Leong et al., 2018). These pathways typically contain genes 
involved in the immune and inflammatory responses (Scriba et al., 2017). Similar to their 
use in cancer, gene signatures of TB can help stratify patients into groups that are likely 
to progress to disease and those that are unlikely to get disease, monitor patient adherence 
to drug regimens, and ensure that infections are being successfully treated. This could be 
particularly important in situations where TB drugs are scarce, or resources for TB 
treatment are reduced, and help improve outcomes for TB treatment. 
RNA Sequencing 
RNA sequencing leverages high throughput sequencing technologies to quantify 
the gene expression levels in a sample. Standard sequencing pipelines involve aligning 
reads to a reference genome and counting the number of genes that overlap with each 
gene or transcript annotation. These raw counts can then be normalized to correct for 
differences in sequencing depth between samples or corrected for unwanted experimental 
variations called batch effects (Johnson, Li & Rabinovic, 2007) . The normalized counts 
can then be merged into a matrix of counts per sample for downstream analysis, which 
often involves identifying significantly differentially expressed pathways or gene 
signatures. Within the R programming language, several software tools have been created 
to make the storage of gene expression data easier. The SummarizedExperiment object 
allows for storage of multiple matrices which can be used to store sample and gene 
annotation data along with raw and normalized count data (Huber et al., 2015) . The 
object can be subset, automatically subsetting the annotation data along with the count 
data to make sure everything remains in sync. 
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Single-Cell RNA Sequencing 
 Typical bulk RNA sequencing combines the expression of genes from all cells in 
a sample. Recently, new techniques for performing single-cell RNA-Seq have been 
developed. These techniques involve either physically separating cells into individual 
wells in a plate or performing highly multiplexed bead-based library preparation for 
higher throughput results (Picelli et al., 2013, Macosko et al., 2015). The end result is 
expression data for an individual cell, allowing researchers to probe differences in gene 
expression across cell types or tumor subgroups. Due to the low amount of starting 
material for each individual cell, scRNA-Seq shows lower gene expression levels than 
typical bulk RNA-Seq datasets and some genes display a bimodal pattern of expression. 
To address these concerns, additional filtering and normalization steps are needed before 
standard RNA-Seq analysis techniques can be performed on scRNA-Seq datasets 
(Brennecke et al., 2013). Further, novel analysis methodologies that take into account the 
missingness that typically arises in scRNA-Seq data have been developed (Finak et al., 
2015, Trapnell et al., 2014, Satija et al., 2015). Choosing which analysis methods to use 
can be dataset specific, and often involves iterating through several analysis techniques 
before settling on the best approach for a given dataset. 
Dissertation Aims 
 The aims in this dissertation seek to develop novel software frameworks and 
pathway signatures to aid in the analysis of bulk and single-cell RNA-Seq datasets in the 
context of disease, specifically breast cancer and tuberculosis. Together, these aims will 
show that by creating interactive and intuitive tools for data processing, users can 
perform sophisticated analysis on RNA-Seq datasets without needing to write code or 
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have a deep understanding of how to run the standard underlying algorithms for RNA-
Seq analysis. 
Aim 1: Create a user-friendly interface and a full-featured analysis toolkit for single-cell 
RNA-Seq datasets 
Many tools for performing single-cell RNA-Seq (scRNA-Seq) analysis exist, but 
these tools are often only available on the command line and require significant 
bioinformatics expertise to use. While other software tools for analysis and visualization 
exist, there has yet to be a full scRNA-Seq analysis tool to help users take raw data 
through a standard pipeline to produce downstream analysis including quality control and 
filtering, visualization with dimensionality reduction methods, differential expression 
analysis, and pathway activity and gene enrichment approaches. In this aim, I present the 
Single Cell Toolkit (SCTK), the first fully interactive scRNA-Seq analysis tool written in 
R and Shiny. This tool allows users to perform a full scRNA-Seq analysis pipeline 
through an intuitive point-and-click interface, allowing improved access to scRNA-Seq 
analysis tools. 
Aim 2: Create and apply oncogenic growth factor receptor network signatures across 
breast cancer cell lines and breast cancer patient tumor samples 
 Cell line derived gene expression signatures have been used to identify signatures 
of pathway activity in cancer samples (Bild et al., 2006). These signatures can then be 
used to stratify samples by cellular activity and predict the effectiveness of drugs that 
target activated oncogenic pathways. In this aim, I describe a new set of pathway activity 
signatures of breast cancer oncogenes in growth factor receptor networks. Pathway 
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activity predictions were performed using Adaptive Signature Selection and Integration 
(ASSIGN) and can be run automatically through extensions of the ASSIGN R package 
(Shen et al., 2015). This set of signatures was applied to cancer cell line panels and 
patient breast cancer tumor samples, revealing additional heterogeneity within the cohorts 
and significant correlations to differences in drug response. 
Aim 3: Collect available biomarkers of tuberculosis disease and progression, create an 
analysis framework to apply these signatures, and profile the pathway activity in a cohort 
of tuberculosis treatment failure samples 
 Several signatures of TB have been previously published and can accurately 
predict several aspects of TB progression into active disease or predict the effectiveness 
of TB treatment. Since numerous unique signatures have been developed, it is worthwhile 
to explore differences in pathway activity across several signatures rather than looking at 
them individually. In this aim, a set of 30 previously published gene signatures of TB 
were collected. To rapidly profile this set of 30 gene signatures we created the TB 
Signature Profiler, a software framework to easily profile a set of samples with a set of 
user defined signatures using common pathway activity prediction algorithms. With this 
tool, users can profile and visualize the pathway activity predictions easily, leveraging the 
SummarizedExperiment object within R to store raw data and pathway activity scores 
together. We used the TB Signature Profiler on a set of TB samples from treatment 
failure patients and identified heterogeneity that showed the published signatures can 
accurately show TB treatment response and highlight issues with adherence to drug 
treatment.
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Chapter 2. An analysis toolkit for single-cell RNA-Seq data 
Adapted from the following manuscript: 
David F. Jenkins, Tyler Faits, Mohammed Muzamil Khan, Emma Briars, Sebastian 
Carrasco Pro, Steve Cunningham, Joshua D. Campbell, Masanao Yajima, and W. Evan 
Johnson. (Manuscript submitted) 
Introduction 
 Single-cell RNA sequencing (scRNA-Seq) techniques allow researchers to 
explore the transcriptional landscape of a sample at the resolution of the individual cell. 
In the context of cancer, scRNA-Seq can identify the subclonality of a tumor sample to 
improve our ability to identify the cell-specific mechanisms that drive tumor growth and 
can characterize different cellular populations within the tumor microenvironment 
(Tirosh et al., 2016, Brady et al., 2017). However, different optimizations of parameters 
and algorithms are required for filtration, normalization, clustering, and differential 
expression of scRNA-Seq data compared to bulk RNA-Seq due to the low amount of 
starting material and technical bias introduced in the common scRNA-Seq library 
preparation techniques (Brennecke et al., 2013). Tools for normalization and analysis of 
scRNA-Seq data exist to overcome these technical biases, but these tools are not 
integrated and require command line processing of samples and knowledge of the many 
options available for each tool, which makes them difficult to use, especially for 
scientists without training in bioinformatics (McCarthy et al., 2017, Nakamura et al., 
2015, Satija et al., 2015, Kharchenko, Silberstein & Scadden, 2014, Fan et al., 2016, 
Trapnell et al., 2014). Even for more advanced users, there is still a need to interactively 
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explore scRNA-Seq results during processing to help make dataset specific decisions that 
can affect downstream analysis. 
 Shiny is an R package and toolkit developed by RStudio 
(https://www.rstudio.com) that allows for the creation of web based graphical user 
interfaces (GUIs) over R packages, allowing for interactive data exploration and analysis 
through familiar drop down menus and buttons (Chang et al., 2017). Users can load a 
Shiny app locally on their computer or the Shiny app can be hosted in the cloud and can 
be accessed through a web browser. 
Package SCATER SC3 SEURAT SCDE PAGODA MONOCLE SCTK 
Filtering and Data 
Summary ü  ü    ü 
Dimensionality 
Reduction ü  ü   ü ü 
Clustering  ü ü  ü ü ü 
Batch Correction   ü ü  ü ü 
Differential 
Expression  ü ü ü  ü ü 
Pathway Enrichment   ü  ü  ü 
Experimental Design       ü 
GUI ü ü   ü  ü 
SingleCellExperiment 
Support ü ü     ü 
Table 2.1. Comparison of SCTK and other popular scRNA-Seq analysis tools. While SCATER (McCarthy et al., 
2017), SC3 (Nakamura et al., 2015), SEURAT (Satija et al., 2015), SCDE (Kharchenko, Silberstein & Scadden, 2014) , 
PAGODA (Fan et al., 2016), and MONOCLE (Trapnell et al., 2014) accomplish some steps in the scRNA-Seq analysis 
pipeline, the SCTK supports a full interactive scRNA-Seq analysis workflow and supports the SingleCellExperiment 
object for data storage. 
 Here, we present the Single Cell Toolkit (SCTK), an R/Shiny based package for 
both command line and interactive scRNA-Seq processing. While other tools can perform 
specific scRNA-Seq analysis steps, the SCTK is the first fully interactive scRNA-Seq 
analysis workflow available within the R language (Table 2.1). We applied the SCTK 
and our workflow on multiple data examples, including stimulated and unstimulated 
mucosal-associated invariant T cells, induced pluripotent stem cells from Yoruba male 
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reference samples to identify batch effects, and tumor cells from breast cancer patients to 
identify pathway activity in response to treatment (Tung et al., 2017, Finak et al., 2015, 
Brady et al., 2017). 
Methods 
 The SCTK is organized into several analysis modules. All modules can be run 
interactively through the Shiny web interface or through the R console. Below we 
describe the datasets available in the SCTK, the underlying architecture of the SCTK, and 
the analysis modules available through the interactive SCTK package and GUI. 
Mucosal-associated Invariant T (MAIT) Cells 
To demonstrate how interactive analysis can be performed in the SCTK, an 
example dataset of mucosal-associated invariant T (MAIT) cells was used 
(Finak et al., 2015). A set of 96 CD8+ MAIT cells were sorted, 47 cells were stimulated 
with cytokines, and the cells were processed and sequenced using the Fluidigm C1 
system. The data was aligned to the human genome, quantified, and included with the 
MAST package. Cytokine stimulation of MAIT cells results in increased cytokine gene 
expression and pathway activity changes that can be identified with differential 
expression analysis and pathway activity analysis, which can serve as an effective control 
for our toolkit methods if cytokine genes and cytokine containing pathways are identified 
through analysis. 
Pluripotent Stem Cells 
A dataset demonstrating batch effects in single-cell data was created by Tung, et. 
al (Tung et al., 2017). Three induced pluripotent stem cell lines were sequenced in 
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triplicate on the Fluidigm C1 platform using a total of 9 plates. The resulting data has a 
clear plate effect that represents an experimental batch effect that could affect 
downstream analysis if it is not corrected. After removing the batch effect, the 
experimental replicates should not separate during analysis, allowing the data to be used 
to identify biological differences between the individuals. 
Data Structure 
Steps in the analysis pipeline are performed on a SCTKExperiment object, an 
extension of the SingleCellExperiment and RangedSummarizedExperiment objects 
developed by the Bioconductor project (Huber et al., 2015). This object is organized into 
identically sized matrices designed to store counts, normalized counts, or batch corrected 
data; a data frame for sample annotation information; and a data frame for feature 
annotation information. These objects allow users to keep their scRNA-Seq data 
organized in a single object that automatically resizes all matrices and annotation 
information if the data is modified, ensuring annotation information and count data is 
always in sync. Additionally, data from dimensionality reduction approaches such as 
principal component analysis (PCA) and t-distributed stochastic neighbor embedding (t-
SNE) can be stored in the object’s reducedDims slot. The SingleCellExperiment object 
has been optimized to store large datasets by using sparse matrices and an efficient API 
to support data that would otherwise not fit into memory using a standard matrix (Lun, 
Pagès & Smith, 2018). Depending on the size of the data stored in the object, the matrices 
used in the object are automatically stored as either standard R matrices, sparse matrices, 
or on disk as a HDF5 file backed matrix. This allows users to take advantage of these 
memory saving strategies automatically without needing to specify which type of matrix 
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that should be used on their dataset. The SingleCellExperiment can also store information 
about spike-in transcripts and sample specific size factors for normalization. By utilizing 
an object that can efficiently store both raw data and downstream analysis results, 
analysis can be performed within the SCTK, saved into the object, and loaded into R for 
additional analysis on the command line. 
The SCTKExperiment is implemented as an S4 object, an object-oriented system 
available within R. This allows users to inherit methods and structure that exists in other 
S4 objects and add additional functionality while still being backwards compatible. The 
SCTKExperiment object also stores the percent variation explained by each principal 
component. This is accomplished by adding an additional slot named pcaVariances to the 
SCTKExperiment object that stores the percent variation explained by each principal 
component (PC) as a DataFrame. The getPCA() function available in the SCTK saves 
the PCs into the reducedDims slot and additionally stores the percent variation explained 
in the pcaVariances slot. This data can be accessed using the pcaVariances() function. 
The SCTKExperiment object can be further extended and will continue to be expanded in 
future versions of the SCTK to store additional single-cell data, annotations, and results. 
Data Upload 
After installing the SCTK, users can start the Shiny app by running the 
singleCellToolkit() function with a SCTKExperiment object as an input to 
automatically load the data into the app. Alternatively, a user can choose to upload a data 
matrix of raw count or normalized data directly through the Shiny app by uploading a 
text file, along with optional sample and feature annotation files. The SCTK will create a 
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SCTKExperiment object to store the toolkit analysis results. This object can be exported 
after analysis has been completed. 
Data Summary and Filtering 
After scRNA-Seq data has been loaded into the SCTK, a table of data summary 
metrics is presented. Because scRNA-Seq data is very sparse, dataset specific filtration 
and normalization can affect downstream analysis (Stegle, Teichmann & Marioni, 2015). 
In the data summary and filtering tab, the SCTK provides users with several summary 
statistics and options for manipulating their data and annotation information. First, within 
the Data Summary subtab, the SCTK displays a table of summary metrics including the 
number of samples, number or genes, average number of reads per cell, average number 
of genes per cell, and the number of genes with few or no counts across all samples. 
Additionally, histograms of the number of counts per sample and the number of 
expressed genes per sample are displayed. If the dataset is small, containing less than 50 
cells, the entire data matrix is also displayed. Using this information, the user can make 
decisions about how best to filter their data for downstream analysis. Users can filter 
genes and samples with low or no expression, delete outlier samples, filter the dataset 
based on annotation information, and modify the annotation information by uploading a 
replacement annotation matrix. For larger datasets, users can also randomly subset their 
data on this tab, allowing the user to perform exploratory analysis on a reduced dataset 
within the SCTK. The filtering applied while using this tab modifies the underlying data 
that is used throughout the app. A snapshot of the original uploaded data is preserved so a 
user can always return to the original uploaded data to restart the analysis or try a 
different filtration protocol. 
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The SCTK doesn’t require users to import their data with a specific set of gene 
annotation information, but some tools within the SCTK are only available if the data 
uses specific gene annotations. Depending on the reference genome that is used during 
sequence alignment and quantification, users may have data that describes their genes 
using gene symbols (e.g. BRCA1), Entrez gene numeric IDs from the NCBI database 
(e.g. 672 for BRCA1), Ensembl gene IDs from the EBI (e.g. ENSG00000012048 for 
BRCA1), or from another source. The SCTK has the ability to convert gene ids to various 
formats using the org.*.eg.db Bioconductor annotation packages. These packages are not 
installed by default, so these must be manually installed before this function will work. 
After these packages have been installed, users can convert between the available gene 
annotations on the Data Summary and Filtering tab. 
Additional modifications to the underlying data object are available in the Assay 
Details subtab. Lists of the available data matrices and reduced dimension data are 
displayed in the Assay Details tab. Users can add additional data matrices to their data 
object. Any existing matrix can be log-transformed, or if raw count data is available, a 
counts per million (CPM) normalization can be applied. Unwanted data matrices or 
reduced dimensionality can be deleted in this tab. 
Finally, in the Visualize subtab, users can visualize gene expression data versus 
annotation data for genes of interest using a boxplot, scatterplot, barplot, or heatmap 
depending on the type of annotation data information that is available. This can be 
helpful for visualizing housekeeping genes for sample quality control, quantifying 
artificial spike-in controls for sequencing quality control, or visualizing individual genes 
of interest. 
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Dimensionality Reduction and Clustering 
Visualization of scRNA-Seq data is crucial to identifying subclusters of cells 
present in the data. Dimensionality reduction techniques allow a user to visualize scRNA-
Seq data by summarizing the observed variation into lower dimension space. PCA 
transforms the matrix into components that describe the variation observed in the data. 
An alternative to PCA, t-distributed stochastic neighbor embedding (t-SNE), is also 
frequently used when analyzing scRNA-Seq data because it is able to embed a large 
amount of variation into a small number of dimensions (Van, Hinton, 2008). When users 
open the dimensionality reduction and clustering tab in the SCTK, a list of available 
reduced dimension datasets and algorithms is provided. Because these algorithms can 
take a long time to compute on large datasets, users can precompute the reduced 
dimension data and store it in a SCTKExperiment object before uploading the data into 
the SCTK. For smaller datasets, users can perform PCA and t-SNE directly through the 
SCTK app. The resulting reduced matrices will be stored in the underlying object that can 
be downloaded when analysis is complete. The resulting data can be displayed in the 
dimensionality reduction and clustering tab. Annotation information can be added to the 
plot by selecting annotations with which to color or shape the points in the scatterplot. 
After visualization of the data, users may want to stratify the scRNA-Seq data into 
clusters that appear during dimensionality reduction. Users can choose to cluster their 
data using k-means clustering, hierarchical clustering, or CLARA (Clustering for Large 
Applications). Clustering is typically performed on the PCA data, because t-SNE data 
does not retain the distance between clusters in its results. After the clustering algorithm 
is complete, the plot is automatically updated to display the resulting clusters. If the user 
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wants to save the cluster results, the cluster assignments can be stored in the annotation 
data frame of the SCTKExperiment object and visualized on other reduced dimension 
data. Additionally, other clustering algorithms can be run on the command line, saved as 
annotation information in the SCTKExperiment object, and visualized in this tab. 
ComBat Batch Correction 
Because of the complexities of the library preparation and the low starting 
material in scRNA-Seq experiments, non-biological variation (batch effects) are present 
and can be a major source of variation present in single-cell experiments (Hicks et al., 
2017). ComBat is a widely used method for adjusting for batch effects in microarray and 
RNA-Seq data (Johnson, Li & Rabinovic, 2007). If users identify variation associated 
with a technical effect, ComBat can be run within the SCTK to remove this variation 
before further downstream analysis. Users can choose an annotation present in the 
annotation data frame and add additional covariates to the ComBat model before 
performing batch correction. After batch correction, the ComBat results are stored as an 
additional assay in the SCTKExperiment object, which can then be used in the other 
analysis tabs within the SCTK. 
Differential Expression and Biomarker Creation 
Differential expression analysis can identify genes that are significantly up or 
down regulated between conditions. While many differential expression algorithms exist, 
their performance may vary on scRNA-Seq datasets. Users can apply common 
differential expression algorithms limma (Ritchie et al., 2015), DESeq2 (Love, Huber & 
Anders, 2014), or perform an ANOVA to identify differentially expressed genes by 
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selecting one or multiple condition variables present in the annotation information. Users 
can customize the differential expression results by changing the number of genes to 
return, the p-value significance cutoff, and the p-value correction method applied to the 
results. The resulting gene list is displayed as a table and also in a heatmap which can 
also be customized. Users can download the gene list directly or create a biomarker list 
for a specific cell type or cell cluster, which can be stored in the gene annotation 
information in the SCTKExperiment object. 
Single-cell RNA-Seq specific tools for differential expression have been 
developed that can adjust for some of the characteristics of scRNA-Seq data. MAST, 
Model-based Analysis of Single-cell Transcriptomics, has been developed to address 
these issues by using a hurdle model (Finak et al., 2015). A hurdle model allows for 
separate accounting of the processes that produce zero count values, and the ones that 
produce the positive count values. MAST allows users to identify this cutoff by using an 
adaptive threshold model that bins genes based on gene expression and identifies a cutoff 
for zero expression. This allows the dropout rate typical of scRNA-Seq data to be 
modelled. Additionally, MAST models the cellular detection rate (CDR), a measure of 
the percent of genes that are expressed in a given sample. Adding the CDR to the model 
can correct for biological and technical covariates when identifying differences in the 
condition of interest. MAST has been implemented within the SCTK. Users can choose 
whether to use MAST’s adaptive thresholding model, choose fold change and expression 
thresholds, and identify significant genes based on conditions present in the annotation 
information provided. The results are presented in a table, violin plots, or visualized in a 
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heatmap and can be saved as a biomarker in the SCTKExperiment object or downloaded 
directly. 
Subsampling and Differential Power Analysis 
The relative complexity of scRNA-Seq experimental designs makes it difficult for 
investigators to ensure that an experiment will have sufficient power while operating on a 
finite budget. Whereas there are tools for optimizing bulk RNA-Seq designs (Busby et 
al., 2013, Guo et al., 2014), these fail to account for the tiered nature of scRNA-Seq 
experiments, where each biological replicate may contribute any number of cells to be 
sequenced, each of which may belong to one of many cell types or subpopulations. Users 
of the SCTK can project estimated power metrics based on their dataset with variable 
simulated parameters including sequencing depth, number of sequenced cells, and 
number of biological replicates. To produce results within a reasonable timespan, the 
Shiny interface only allows users to vary one parameter at a time while keeping the 
others fixed. The command line allows users to probe all parameters at once, producing 
multidimensional power estimates which will help investigators optimize their scRNA-
Seq experimental designs. 
Pathway Activity Analysis 
Gene expression measurements can be summarized into a signature or set of 
genes to create a score that represents the activity of that set of genes in a sample. By 
summarizing genes in known signaling pathways, cells with active signaling pathways or 
specific cellular functions can be identified. Gene Set Variation Analysis (GSVA) uses 
gene sets to create these signatures (Hänzelmann, Castelo & Guinney, 2013). The 
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molecular signature database (MSigDb) is a database of molecular signatures that can be 
used in GSVA (Liberzon et al., 2011). GSVA has been implemented in the SCTK. Users 
can select their input data, gene set(s), and GSVA parameters interactively through the 
app. GSVA can be run across all MSigDB signatures, a user selected subset of MSigDB 
signatures, or a set of custom gene signatures saved as annotation columns in the 
rowData slot of the SCTKExperiment object. After GSVA is complete, scores will be 
displayed in either violin plots or a heatmap on the Pathway Activity tab of the SCTK. 
Users can save the pathway activity scores into the annotation data columns of the 
SCTKExperiment object or download the scores directly. 
Results 
The SCTK allows users to analyze data interactively through the Shiny web 
interface, or perform command line analysis and visualize the results when the analysis is 
complete. Interactive analysis works best for smaller studies of several hundred cells, 
which typically come from plate-based technologies such as SMART-Seq or CEL-Seq 
where cells are physically sorted into 96-well plates (Picelli et al., 2013, Hashimshony et 
al., 2016). For larger datasets, such as those created through commercially available tools 
such as the 10x Chromium Single Cell Solution and other droplet-based high throughput 
methods, analysis modules in the SCTK can be run on the command line, saved in the 
SCTKExperiment object, and loaded into the toolkit for efficient visualization (Macosko 
et al., 2015). To demonstrate a standard analysis workflow in the SCTK, two example 
datasets will be used. Equivalent analysis will be shown through the interactive modules 
and through the functions available on the R console. 
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Data Upload 
To demonstrate how interactive analysis can be performed in the SCTK, we will 
begin using the MAIT cell example. The MAIT cell example should separate by 
experimental condition (cytokine stimulated vs unstimulated) and genes identified 
through differential expression and pathways identified through pathway activity analysis 
should be associated with cytokine stimulation. 
To upload data into the toolkit for interactive analysis, data was extracted from 
the MAST package and the TPM matrix, sample annotations, and gene annotations were 
saved as tab separated text files. After starting the SCTK, the data can be uploaded on the 
“Upload” tab by selecting the text files and clicking upload (Figure 2.1). Optionally, the 
user can select “Create log(counts) assay” to store both the originally uploaded counts 
and a log transformed matrix. 
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Figure 2.1. Single Cell Toolkit upload tab. Users can choose between uploading data through file upload boxes or 
preloaded example datasets. When the user clicks the ‘Upload’ button, the app creates a SCTKExperiment object to 
store raw data and analysis. 
To perform analysis using the R functions available in the SCTK, the MAST data 
first must be loaded into a SCTKExperiment object. This can be accomplished with the 
createSCE() function. 
R> library(MAST) 
R> library(singleCellTK) 
R> library(xtable) 
R> data(maits, package="MAST") 
R> maits_sce <- createSCE(assayFile = t(maits$expressionmat), 
 +                        annotFile = maits$cdat, 
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 +                        featureFile = maits$fdat, 
 +                        assayName = "logtpm", 
 +                        inputDataFrames = TRUE, 
 +                        createLogCounts = FALSE) 
Data Summary and Filtering 
On the second tab in the interactive toolkit, a table of summary metrics is 
rendered. Additionally, the user is provided with several options for filtering data and 
modifying the underlying SCTKExperiment object. The MAIT dataset contains an 
annotation column called “ourfilter.” The “Filter samples by annotation” filter was used 
to subset the original dataset of 96 cells to remove all cells that do not pass the filter, 
leaving 74 cells (Figure 2.2). This filter subsets all data assays, cell annotation data, and 
gene annotation data present in the SCTKExperiment object. The singleCellTK has the 
ability to convert gene ids to various formats in the “Convert Gene Annotation” section 
of the data summary and filtering page by selecting the organism, the source annotation 
type, and the annotation type to convert the gene annotations to. 
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Figure 2.2. Single Cell Toolkit Data Summary and Filtering tab. In the right panel, a table of data summary metrics 
and a heatmap of counts per sample is displayed. The original 96 cells in the MAIT data are filtered to remove all 
samples that do not pass the “ourfilter” annotation column in the dataset using the “Filter samples by annotation” filter. 
74 pass filter cells remain. Additional tools for data filtering are available in the left column. 
In the R console, the summarizeTable() function produces summary metrics 
from a SCTKExperiment object. The user selects the assay to summarize and the table of 
summary metrics is produced (Table 2.2). Typically, these summary statistics would be 
run on a "counts" matrix, but the MAIT SCTKExperiment object only contains log(tpm) 
values so the average number of reads per cell is calculated from the normalized values 
instead of raw counts. 
R> summarizeTable(maits_sce, useAssay = "logtpm") 
Metric Value 
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Number of Samples 96 
Number of Genes 16302 
Average number of reads per cell 17867 
Average number of genes per cell 6833 
Samples with <1700 detected genes 5 
Genes with no expression across all samples 0 
Table 2.2. Table of summary metrics produced by the summarizeTable() function. Five of the 96 cells in the 
MAIT dataset have fewer than 1,700 detected genes, indicating that these cells may have failed sequencing and should 
be removed for downstream analysis. 
Sample annotation information is available in the colData data frame in the 
SCTKExperiment object. The “ourfilter” annotation can be used to subset the data within 
the SCTKExperiment object. 
R> summarizeTable(maits_sce, useAssay = "logtpm") 
R> colnames(colData(maits_sce)) 
 [1] "wellKey"          "condition"        "nGeneOn" 
 [4] "libSize"          "PercentToHuman"   "MedianCVCoverage" 
 [7] "PCRDuplicate"     "exonRate"         "pastFastqc" 
[10] "ncells"           "ngeneson"         "cngeneson" 
[13] "TRAV1"            "TRBV6"            "TRBV4" 
[16] "TRBV20"           "alpha"            "beta" 
[19] "ac"               "bc"               "ourfilter" 
R> table(colData(maits_sce)$ourfilter) 
FALSE  TRUE  
   22    74  
R> maits_subset <- maits_sce[, colData(maits_sce)$ourfilter] 
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To convert gene annotations in the R console, the convertGeneIDs() function 
can be used. Annotations can be converted between various formats available within the 
org.*.eg.db Bioconductor annotation packages which must be installed separately. 
R> library(org.Hs.eg.db) 
R> maits_entrez <- maits_subset 
R> maits_subset <- convertGeneIDs(maits_subset, inSymbol = "ENTREZID", 
 +                                outSymbol = "SYMBOL", 
 +                                database = "org.Hs.eg.db") 
Dimensionality Reduction 
Next, the data is visualized in the Dimensionality Reduction and filtering tab. 
First, the ‘logcounts’ assay was selected. Since the PCA was not precalculated for this 
assay, PCA is performed, stored in the SCTKExperiment object, and then used for 
visualization in the scatter plot. The ‘condition’ variable in the colData annotation assay 
describes whether or not the cell was stimulated. There is a clear separation in the first 
principal component between stimulated and unstimulated cells, indicating a biological 
difference between the two cell conditions (Figure 2.3). 
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Figure 2.3. Single Cell Toolkit Dimensionality Reduction and Clustering tab. Since no PCA values were present in 
the object, they are calculated, stored in the reducedDim slot in the object, and the first two principal components are 
displayed in the scatterplot. By selecting ‘condition,’ the points are colored by the condition column of the colData 
annotation assay in the SCTKExperiment object. 
Dimensionality reduced data is stored in the reducedDims slot of the 
SCTKExperiment object, which can be accessed with the reducedDims() function. PCA 
and t-SNE data can be added to the object with the getPCA() and getTSNE() functions. 
In addition to storing the principal components in the reducedDims slot, the getPCA() 
function stores the percent variation explained by each principal component in the 
pcaVariances slot. 
R> maits_subset <- getPCA(maits_subset, useAssay = "logtpm", 
 +                        reducedDimName = "PCA_logtpm") 
R> maits_subset <- getTSNE(maits_subset, useAssay = "logtpm", 
 +                         reducedDimName = "TSNE_logtpm") 
R> reducedDims(maits_subset) 
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 List of length 2 
 names(2): PCA_logtpm TSNE_logtpm 
PCA and t-SNE data can be visualized with the plotPCA() and plotTSNE() 
functions, respectively. 
R> plotPCA(maits_subset, reducedDimName = "PCA_logtpm", 
 +         colorBy = "condition") 
R> plotTSNE(maits_subset, reducedDimName = "TSNE_logtpm", 
 +          colorBy = "condition") 
Similar to the PCA visualization, there is a clear separation between the 
stimulated and control cells in the t-SNE visualization (Figure 2.4). 
 
Figure 2.4. Result of plotTSNE() on the MAIT dataset. There is a clear separation between the stimulated and 
unstimulated MAIT cells. One sample marked as stimulated clusters with the other unstimulated cells. This could 
indicate a mislabeled sample. 
Differential Expression with MAST 
Differential expression analysis can identify the genes associated with the 
biological difference induced by cytokine stimulation that was identified during 
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visualization with PCA. The MAST differential expression tab was used on the logcounts 
assay. The default options (Use adaptive thresholding, minimum fold change of 0.6, 0.1 
expression threshold of 0.1, and an FDR cutoff of 0.05) were used in accordance with the 
MAST package example vignette (Finak et al., 2015). 
 
Figure 2.5. Single Cell Toolkit MAST tab. One available visualization of the MAST differential expression results is 
a plot of expression values vs standardized cellular detection rate for the top significantly expressed genes. 
MAST analysis can be run by selecting the analysis options on the MAST page 
and clicking the “Run DE Using Hurdle” button. After MAST analysis completed, the 
953 significant genes could be visualized as a result gene table, a set of violin plots, a 
heatmap, or a set of linear models of logtpm values vs cellular detection rate (Figure 2.5). 
Among the top differentially expressed genes was interferon gamma, a cytokine that is 
known to be produced in response to stimulation. The resulting significant gene list can 
be downloaded at the bottom of the tab. 
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To run MAST analysis through the R console on a SCTKExperiment object, first 
run adaptive thresholding on the object. After adaptive thresholding is complete, the 
MAST() function in the SCTK can be used. After MAST analysis is complete, the 
MASTviolin(), MASTregression(), and plotDiffEx() functions can be used to 
visualize the results (Figure 2.6). 
R> thresholds <- thresholdGenes(maits_subset, useAssay = "logtpm") 
R> mast_results <- MAST(maits_subset, condition = "condition", 
 +                      useThresh = TRUE, useAssay = "logtpm") 
R> MASTviolin(maits_subset, useAssay = "logtpm", 
 +            fcHurdleSig = mast_results, threshP = TRUE, 
 +            condition = "condition", samplesize = 16) 
R> MASTregression(maits_subset, useAssay = "logtpm", 
 +                fcHurdleSig = mast_results, threshP = TRUE, 
 +                condition = "condition", samplesize = 16) 
R> plotDiffEx(maits_subset, useAssay = "logtpm", 
 +            condition = "condition", 
 +            geneList = mast_results$Gene[1:100], 
 +            annotationColors = "auto", 
 +            displayRowLabels = FALSE, displayColumnLabels = FALSE) 
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Figure 2.6. MAST result visualizations available in the SCTK. a. The thresholdGenes() function bins genes 
based on expression profile and displays a density plot for each bin. The red line indicates the cutoff for zero 
expression. b. The MASTviolin() function displays the top differentially expressed genes using a violin plot. c. The 
MASTregression() function displays the top differentially expressed genes and the CDR used in the model d. The 
plotDiffEx() function can be used to display a heatmap of a set of differentially expressed genes. 
Pathway Activity Analysis with GSVA 
To identify gene lists that show differences in pathway activity level between 
unstimulated and stimulated cells, the GSVA tab was used. GSVA was used to calculate 
pathway activity levels for all pathways in MSigDB c2. The 50 top significantly different 
pathway gene lists when comparing stimulated vs unstimulated cells were displayed as 
violin plots (Figure 2.7). Among the top pathways that showed increased activity in the 
stimulated cells was KEGG_PROTEASOME, indicating proteasome related genes 
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showed increased activity in the stimulated T cells. This pathway includes interferon 
gamma. The pathway results can be downloaded at the bottom of the pathway activity 
analysis tab. 
 
Figure 2.7. Single Cell Toolkit Pathway Activity Analysis tab. Currently GSVA is supported. Users can choose to 
manually input a gene list or use a subset or all of the gene lists in MSigDB c2. After clicking ‘Run’ users can visualize 
a heatmap or violin plot of results if a condition of interest is given. Results can be downloaded or saved into the 
SCTKExperiment object. 
The gsvaSCE() function can be used to run GSVA on an SCTKExperiment 
object using signatures from MSigDB. Currently, the SCTKExperiment object must use 
Entrez Gene IDs. Users can run GSVA using the full set of MSigDB signatures or a 
subset of signatures. The signatures run below are known to separate the stimulated and 
unstimulated cells: 
R> gsvaRes <- gsvaSCE(maits_entrez, useAssay = "logtpm", 
 +              "MSigDB c2 (Human, Entrez ID only)", 
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 +              c("KEGG_PROTEASOME", 
 +              "REACTOME_VIF_MEDIATED_DEGRADATION_OF_APOBEC3G", 
 +              "REACTOME_P53_INDEPENDENT_DNA_DAMAGE_RESPONSE", 
 +              "BIOCARTA_PROTEASOME_PATHWAY", 
 +              "REACTOME_METABOLISM_OF_AMINO_ACIDS", 
 +              "REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE", 
 +              "REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION", 
 +              "REACTOME_STABILIZATION_OF_P53", 
 +              "REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1"), 
 +              parallel.sz=1) 
R> gsvaPlot(maits_subset, gsvaRes, "Violin", "condition", text_size=5) 
R> gsvaPlot(maits_subset, gsvaRes, "Heatmap", "condition", 
 +          show_column_names = FALSE, text_size = 5) 
After performing GSVA, the gsvaPlot() function can be used to produce a set of 
violin plots or a heatmap of the GSVA results (Figure 2.8). 
 
Figure 2.8. Pathway activity heatmap from the gsvaPlot() function. The results of GSVA pathway activity 
analysis can be visualized using a heatmap. If a condition of interest is chosen, a color bar is displayed on the top of the 
heatmap indicating the condition. 
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Single-Cell Batch Effects 
We used the induced pluripotent stem cell line data to demonstrate the SCTK’s 
ability to detect and correct for batch effects (Tung et al., 2017). In this dataset, three 
reference samples were prepared and sequenced in triplicate separately in order to 
introduce an experimental batch effect. Because these initial samples were identical, any 
difference between the replicates of the same sample represent an unwanted technical 
effect that could affect downstream analysis to identify biological differences between 
the samples. 
 
Figure 2.9. PCA before and after ComBat batch correction. The three replicates show a clear separation in the 
log(counts) data (left), which is corrected after running ComBat (right). 
The dataset was downloaded and loaded into the SCTK. In order to reduce the 
effect of genes with low or no expression, cells with less than 1,700 detected genes and 
genes with average expression in the bottom 50 percent of the dataset were removed 
using the filtering tab. The three replicates from the NA19239 sample were used for 
downstream analysis. The resulting filtered data was visualized on the Dimensionality 
Reduction and Clustering tab. The batch effect resulting from the plate effect was clearly 
seen in the data from the log(molecules) assay (Figure 2.9, left). ComBat was run on the 
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log(molecules) assay using default parameters (replicate as batch condition, no additional 
covariates, parametric combat) and saved in an assay named “combat”. The 
Dimensionality Reduction and clustering tab was then used to visualize a PCA of the 
combat assay (Figure 2.9, right). After ComBat, the plates display no signs of batch 
effects in the first two principal components, indicating that the technical plate artifact 
has been removed. 
The ComBatSCE() function can be used to perform ComBat batch correction on a 
SCTKExperiment object. Batch effects can be visualized using reduced dimension data, 
using functions such as plotPCA() and plotTSNE(). To perform this analysis on the R 
console, first the data must be loaded and subset to contain the NA19239 samples only. 
R> library(GEOquery) 
R> #download data from GEO 
R> GSE77288 <- getGEO('GSE77288', GSEMatrix=TRUE) 
R> con <- gzcon(url(paste( 
 +   "ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE77nnn", 
 +   "GSE77288/suppl", 
 +   "GSE77288_molecules-raw-single-per-sample.txt.gz", sep="/"))) 
R> txt <- readLines(con) 
R> dat <- read.table(textConnection(txt), sep = "\t", header=T) 
R> #extract annotation data from the GSE record 
R> pdatasub <- pData(GSE77288$GSE77288_series_matrix.txt.gz)[ 
 +   pData(GSE77288$GSE77288_series_matrix.txt.gz)$title %in%  
 +     paste(as.character(dat[,1]), as.character(dat[,2]), 
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 +           as.character(dat[,3]), sep="-"),] 
R> rownames(pdatasub) <- pdatasub$title 
R> #transform the count matrix 
R> datsub <- t(dat[, 4:ncol(dat)]) 
R> colnames(datsub) <- paste(as.character(dat[,1]), 
 +                           as.character(dat[,2]), 
 +                           as.character(dat[,3]), sep="-") 
R> #create SCtkExperiment object 
R> GSE77288_sce <- createSCE(assayFile = datsub, 
 +                           annotFile = pdatasub, 
 +                           inputDataFrames = T) 
R> #subset data to NA19239 only 
R> GSE77288_sce <- GSE77288_sce[ , 
 +   colData(GSE77288_sce)[,"individual:ch1"] == "NA19239"] 
R> #remove genes with no expression across all cellss 
R> GSE77288_sce <- GSE77288_sce[ 
 +   rowSums(assay(GSE77288_sce, "counts")) != 0, ] 
R> #log transform the count matrix 
R> assay(GSE77288_sce, "logcounts") <- log2(assay(GSE77288_sce) + 1) 
R> #plot before combat 
R> plotPCA(GSE77288_sce, useAssay = "logcounts", runPCA = T, 
 +         colorBy = 'replicate:ch1') 
R> #run combat 
R> assay(GSE77288_sce, "combat") <- ComBatSCE(GSE77288_sce, 
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 +                                            batch = "replicate:ch1") 
R> #plot after combat 
R> plotPCA(GSE77288_sce, useAssay = "combat", runPCA = T, 
 +         colorBy = 'replicate:ch1') 
Discussion 
We have developed the Single Cell Toolkit (SCTK), a framework for analyzing 
and visualizing scRNA-Seq data interactively in R. With this toolkit users can process 
data, visualize the results, and save the data into a convenient object for further 
downstream analysis. Because the SCTK uses the SCTKExperiment object, the resulting 
data object is compatible with other tools that accept SummarizedExperiment or 
SingleCellExperiment objects. The toolkit supports various use cases from a user who 
just wants to visualize preprocessed analysis stored in a data object to a user who wants 
to perform a full scRNA-Seq pipeline from filtering to pathway activity analysis. The 
SCTK is the first fully interactive toolkit that allows a user to perform a standard scRNA-
Seq workflow from uploading a count matrix to differential expression and pathway 
activity analysis without writing any code. 
Additionally, we have used the analysis workflow available in the SCTK to 
identify pathway activity differences between breast cancer cells before and after drug 
treatment. By performing pathway activity analysis on this dataset, we found significant 
increases in receptor tyrosine kinase (RTK) and epithelial to mesenchymal transition 
(EMT) pathways, indicating the SCTK can be used to identify biologically meaningful 
results. (Brady et al., 2017). 
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We demonstrated the SCTK is an effective analysis tool by presenting a 
differential expression analysis and pathway activity prediction workflow for MAIT 
cells, and batch correction with ComBat on a set of three technical replicates of a Yoruba 
male reference sample. These workflows show the flexibility and interactive capability of 
the SCTK, which is not possible in any other currently available R package. 
The SCTK is flexible and additional analysis modules will be added over time. 
Future improvements include additional ways to normalize input data including using 
ERCC spike in information, scRNA-Seq specific methods for pathway activity analysis 
and ComBat batch correction, additional analysis modules, and additional updates to the 
SCTKExperiment object to store additional results and downstream analysis and support 
nested study designs where cells in an experiment come from various donors or tissues. 
Software Availability 
The SCTK is freely available through Bioconductor 
(https://bioconductor.org/packages/devel/bioc/html/singleCellTK.html) and GitHub 
(https://github.com/compbiomed/singleCellTK). Detailed installation instructions are 
available on the SCTK help website (https://compbiomed.github.io/sctk_docs/). 
Acknowledgments 
We thank the Boston University MSSP consulting services, Zijian Han, Ziyan Li, 
Zichun Liu, Shiyi Yang, and Ada McFarlane for contributions to the MAST wrapper 
code. This research was supported by U01CA220413 from the NIH. 
  
37 
Chapter 3. Oncogenic growth factor receptor network signatures in TCGA and 
metastatic breast cancer 
Adapted from the following manuscript: 
Mumtahena Rahman†, Shelley M. MacNeil†, David F. Jenkins†, Gajendra Shrestha, 
Sydney R. Wyatt, Jasmine A. McQuerry, Stephen R. Piccolo, Laura M. Heiser, Joe W. 
Gray, W. Evan Johnson and Andrea H. Bild. 2017. "Activity of distinct growth factor 
receptor network components in breast tumors uncovers two biologically relevant 
subtypes." Genome Medicine 9 (1): 40. 
†Contributed equally 
Introduction 
 Breast cancer remains one of the leading causes of cancer-related death in women 
(DeSantis et al., 2014). It is well established that growth factor receptors and their 
downstream signaling pathways, contribute to breast cancer proliferation, survival, and 
metastasis (Lemmon, Schlessinger, 2010, Mosesson, Yarden, 2004). Molecular 
aberrations can occur in various growth factor receptor network (GFRN) members and 
have been described in breast cancer (Nahta, Hortobágyi & Esteva, 2003, Hynes, 2000, 
Masuda et al., 2012). These findings have paved the way for GFRN-targeted treatments 
which are currently approved for use and being evaluated in various stages of clinical 
development and in clinical trials (De Abreu et al., 2014, Davis et al., 2014). Although 
these treatments do hold promise, relatively few data are available on the cooperativity 
and diversity of complicated GFRN signaling in actual breast tumors. Additionally, 
assessing GFRN activity in patient tumors is extremely challenging due to the lack of 
methods capable of measuring signaling events in tumors. Drug selection is often guided 
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by expression of protein biomarkers, and drug resistance often develops due to 
compensation by interacting pathways within the GFRN (Groenendijk, Bernards, 2014, 
McCubrey et al., 2012). Therefore, there is a strong need to develop better methods for 
measuring and understanding GFRN signaling events in breast tumors in order to deliver 
the most effective treatment regimens and combat drug resistance (Lemmon, 
Schlessinger, 2010, Groenendijk, Bernards, 2014, Perona, 2006). 
 Growth factor receptors, such as epidermal growth factor receptor 1 (EGFR), 
human epidermal growth factor receptor 2 (HER2), and insulin-like growth factor 1 
receptor (IGF1R), are key regulatory nodes of the GFRN and are often aberrantly 
activated across breast cancer subtypes (Masuda et al., 2012, Iqbal, Iqbal, 2014, 
Farabaugh, Boone & Lee, 2015). Approximately 15–30% of breast cancer patients are 
diagnosed with HER2-positive breast cancer, which is characterized by amplification of 
HER2 (Iqbal, Iqbal, 2014). EGFR amplifications occur in 25% of all triple-negative 
breast cancer (TNBC) patients and are often associated with poor outcomes (Masuda et 
al., 2012, Davis et al., 2014, Perou, Charles M., 2010). High IGF1R activity occurs in up 
to 50% of breast tumors and is seen across all breast cancer subtypes (Farabaugh, Boone 
& Lee, 2015). These receptors can activate downstream oncogenic growth cascades such 
as the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
pathways, forming a complex, interconnected, and dynamic signaling network (Lemmon, 
Schlessinger, 2010, Davis et al., 2014). Activation of PI3K by growth factor receptors 
triggers the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway, leading to cell 
proliferation, metabolic changes, and cell survival (Baselga, 2011, Paplomata, O'Regan, 
2014, Saini et al., 2013). In the MAPK pathway, following growth factor receptor 
  
39 
activation, RAS becomes activated followed by activation of RAF1, MEK, and ERK, 
leading to transcriptional changes that impact cellular proliferation, motility, and evasion 
of apoptosis (Masuda et al., 2012, Davis et al., 2014, Santen et al., 2002, Roberts, Der, 
2007). Both the PI3K and MAPK pathways contribute to tumor progression by disrupting 
the balance of pro- and anti-apoptotic proteins of the BCL-2 protein family in the 
mitochondrial (also known as intrinsic) pathway of apoptosis (Czabotar et al., 2014, Vo, 
Letai, 2010). Particular GFRN members can upregulate anti-apoptotic proteins such as 
BCL-2, BCL-XL, and MCL-1 and downregulate pro-apoptotic proteins such as BAD, 
BAX, and BIM, all of which contribute to apoptosis evasion and resistance to cancer 
treatments in patients (Letai, 2008, Datta et al., 1997, Franke et al., 2003, Townsend et 
al., 1998, Carpenter, Lo, 2013, Weston et al., 2003, Ley et al., 2003, Deng et al., 2007). 
ERBB receptor tyrosine kinases, such as EGFR and HER2, have a great deal of overlap 
in the downstream pathways they activate; however, individual ERBB receptors have the 
capability to preferentially bind particular downstream signaling molecules (Arteaga, 
Engelman, 2014, Yarden, Sliwkowski, 2001). Furthermore, preclinical studies have 
shown that EGFR- and HER2-driven cancers show differential response to targeted 
therapies. EGFR mutant cancers are less responsive to single-agent PI3K/AKT inhibitors 
in comparison to HER2-amplified cancers and require the inhibition of both the PI3K and 
MEK pathways (Faber et al., 2009). These suggest that ERBB proteins can couple to 
distinct signaling pathways and invoke non-redundant physiological effects, which 
warrants for specificity for the different GFRN components. Therefore, an accurate 
assessment of global GFRN activity is pivotal for selecting targeted treatment strategies 
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that consider the diversity of growth and cell survival mechanisms in breast cancer 
patients. 
 Despite advances in the cellular and molecular characterization of breast cancer, 
effective personalized breast cancer treatment remains elusive. Immunohistochemical and 
gene expression profiling-defined breast cancer molecular classification has advanced our 
understanding of breast cancer prognosis, treatment, and improved survival. Currently, 
breast cancers are stratified into different clinical subtypes in order to determine specific 
treatments, and several breast cancer subtyping approaches are currently available. For 
example, fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) 
techniques are often used to determine clinical subtypes based on common receptor 
protein alterations such as estrogen (ER), progesterone (PR), and HER2 receptor 
amplification (De Abreu et al., 2014, Weigel, Dowsett, 2010). Additionally, Ki-67 
(proliferation marker), CK 5/6 (cytokeratin marker), EGFR, androgen receptor (AR), and 
p53 (apoptosis marker) are used as biomarkers to further classify breast cancer using IHC 
methods. Although helpful, IHC methods are often subjected to bias due to tissue 
handling, fixation, antibody sources, and need for physical evaluation by pathologists 
(Hammond et al., 2010, Wolff et al., 2013). More recently, Perou and Sørlie et al. 
proposed five “intrinsic subtypes” that have shown utility in guiding therapy by 
leveraging gene expression data, differences in clinical outcomes, and responses to 
neoadjuvant chemotherapy (Perou, 2010, Parker et al., 2009, Sørlie et al., 2001, De 
Abreu et al., 2014, Patani, Martin & Dowsett, 2013). Further, evaluation of gene 
expression has led to the proposition of several additional subtypes, including claudin-
low, molecular apocrine, and a novel luminal-like subtype (Herschkowitz et al., 2007, 
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Prat et al., 2010, Vera-Badillo et al., 2014, Farmer et al., 2005, Guedj et al., 2012, 
Dvorkin-Gheva, Hassell, 2014). While molecular subtypes continue to emerge, routine 
use of such subtypes in clinical settings is not sensitive and specific due to some critical 
limitations. For example, tumors of the same clinical or intrinsic subtype can show 
differences in growth, survival, and response to therapies, and clinical and intrinsic 
subtypes are sometimes discrepant (Marusyk, Polyak, 2010, Huang et al., 2012). 
Approximately one-third of HER2+ tumors are not classified as the HER2-enriched 
intrinsic subtype and up to 25% of clinically characterized ER+ tumors are not classified 
as the luminal intrinsic subtype (Parker et al., 2009). While IHC methods are single 
protein based, intrinsic subtypes are fundamentally empirical and do not focus on distinct 
biological properties. Thus, both IHC and intrinsic subtypes fail to recapitulate the 
biological heterogeneity within each subtype (Cheang et al., 2015). Recent studies 
highlight the discordance between the IHC and intrinsic subtypes, which calls for 
additional work (Cheang et al., 2015, Tang, Tse, 2016). To address these challenges, 
pathway-level subtyping may provide complementary information for determining 
therapeutic targets. For example, identification of specific aberrant pathways within the 
triple negative and basal-like subtypes may help to explain additional heterogeneity and 
better target these subtypes pharmacologically (Badve et al., 2011). Here, breast cancer 
inter-tumor heterogeneity was explored in terms of GFRN activity for its well-known role 
in growth, evasion of apoptosis, and drug response. 
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Figure 3.1. High-level overview for probing growth factor receptor networks in breast cancer. a. Overexpression 
of growth factor receptor network (GFRN) genes in human mammary epithelial cells (HMECs): AKT, BAD, EGFR, 
HER2, IGF1R, RAF1, and KRAS (G12V). b. Generation of RNA sequencing data from HMECs overexpressing GFRN 
genes and signature generation using ASSIGN. c. Determination of GFRN pathways activation across TCGA breast 
tumors and ICBP breast cancer cell lines and identification of novel phenotypes based on GFRN activity. d. Linking 
novel phenotypes to survival and drug response mechanisms in biochemical and drug response assay. 
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 While biochemical measurement of pathway activity is challenging in human 
tumors due to limited tissue availability and instability of specific proteins, patterns of 
activity across multiple genes—or gene expression signatures—can be used as surrogates 
for pathway activation in tumors and to model biological phenotypes (Bild et al., 2006, 
Watters, Roberts, 2006, Cohen et al., 2011, Soldi et al., 2013, El-Chaar et al., 2014). 
Pathway activation has been used to predict drug response to targeted therapies in cell 
lines (Cohen et al., 2011, El-Chaar et al., 2014, Gustafson et al., 2010), but to the best of 
our knowledge, this is the first study which measures activity of seven GFRN members 
concurrently at the pathway level in patient samples. In this study, 1,119 breast tumors 
were profiled for GFRN activity across The Cancer Genome Atlas (TCGA) and across 55 
breast cancer cell lines from the Integrative Cancer Biology Program (ICBP43) (Figure 
3.1) (Cancer Genome, 2012, Daemen et al., 2013). Pathway activity was estimated in 
samples using novel GFRN gene expression signatures for the HER2, IGF1R, AKT, 
EGFR, KRAS (G12V mutation), RAF1, and BAD pathways. These GFRN signatures 
were generated by performing sequencing on RNA collected from primary human 
mammary epithelial cells (HMECs) overexpressing HER2, IGF1R, AKT1, EGFR, KRAS 
(G12V), RAF1, or BAD for 18–36 h. These signatures capture early transcriptional 
events, which occur shortly after oncogene activation, and represent the transcriptional 
profile of pathway activation, and not of a transformed cell. 
 Using the pathway analysis toolkit Adaptive Signature Selection and InteGratioN 
(ASSIGN), the signatures were projected onto each breast cancer data set and uncovered 
two discrete patterns of GFRN activity (Shen et al., 2015). One pattern was characterized 
by concurrent activation of the HER2, IGF1R, and AKT pathways, and another was 
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characterized by concurrent activation of the EGFR, KRAS, RAF1, and BAD pathways. 
Typically, when one set of pathways was active, the other set was inactive, indicating that 
each sample tends to have a dominant GFRN phenotype. Pathways activation of HER2, 
IGF1R, and AKT was nicknamed the “survival phenotype” and activation of EGFR, 
KRAS, RAF1, and BAD as the “growth phenotype”. These names were chosen for 
simplicity and based on the known role of AKT signaling in cancer cell survival and the 
known role of EGFR/RAS signaling in cellular growth (Zhang, Liu, 2002, McCubrey et 
al., 2007). Importantly, genomic pathway activity corresponded to apoptotic phenotypes. 
The growth phenotype showed upregulation of anti-apoptotic protein MCL-1 and 
downregulation of pro-apoptotic protein BIM as a mechanism of escaping apoptosis. 
Additional subgroups were also identified within each phenotype, including HER2 high 
and HER2 low activity groups within the survival phenotype and BAD high and BAD 
low activity groups within the growth phenotype. These discrete subgroups displayed 
differences in response to targeted therapies and chemotherapies. Therefore, these 
phenotypes can serve as surrogates for GFRN activity that capture significant variability 
in the gene expression data, differentiate survival mechanisms, and correlate to drug 
response significantly. A major component of the heterogeneity found across tumor 
expression data was contributed by GFRN signaling and was independent of ER, PR, and 
HER2 status compared to intrinsic subtypes. Additionally, a unique aspect is that GFRN 
activity explained the data in a biologically meaningful way. For example, while intrinsic 
subtyping approaches are based on empirical patterns of gene expression and do not 
necessarily represent a biological process, the subgrouping approach represents aberrant 
activity in specific GFRN pathway signaling. Therefore, pathway-based phenotypes and 
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subgroups have the potential to complement existing methods and identify biologically 
and clinically relevant patterns in tumors. Taken together, pathway signatures not only 
aid in assessing general pathway activity patterns in a biologically relevant way, but also 
show promise to select better treatment targets for breast cancer patients. 
Methods 
Overexpression of genes of interest in human mammary epithelial cells 
 
Figure 3.2. Validation of protein overexpression for each GFRN signature. Protein lysates from human primary 
mammary epithelial cells (HMECs) overexpressing GFRN genes were compared to GFP control protein lysates using 
Western blotting. a. HMECs overexpressing AKT1 compared to GFP (GAPDH loading control) b. HMECs 
overexpressing BAD, compared to GFP (βtubulin loading control) c. HMECs overexpressing EGFR and pEGFR 
compared to GFP (GAPDH loading control) d. HMECs overexpressing HER2 and pHER2 compared to GFP (GAPDH 
and β-tubulin loading controls) e. HMECs overexpressing IGF1R and pIGF1R (GAPDH and β-tubulin loading 
controls) f. HMECs overexpressing pMEK compared to GFP (β-tubulin and GAPDH loading controls) g. HMECs 
overexpressing RAF1 compared to GFP controls (β-tubulin loading controls). 
In order to create gene expression signatures representative of pathway activation, 
GFRN oncogenes were overexpressed in HMECs. HMECs from a non-cancer-related 
breast reduction surgery performed at the University of Utah were isolated and cultured 
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according to previously published protocols (Ian Freshney, Freshney, 2004). Cells were 
grown in serum-free mammary epithelial basal medium (MEBM) plus the addition of a 
“bullet kit” (Lonza) and supplemented with 5 mg/ml transferrin and 10-5 M isoproterenol 
at 5% CO2. Cells were brought to quiescence by growth in low serum conditions (0.25% 
MEBM + bullet kit, no EGF) for 36 hours. Cells were infected with recombinant 
adenovirus (at 500 MOI) expressing either human oncogenes AKT1, IGF1R, BAD, 
HER2, KRAS (G12V), and RAF1 or GFP control (Figure 3.2). Cells were incubated with 
virus for 18 hours except for KRAS (G12V), which was incubated for 36 hours. The 
adenoviral expression systems invoke transient gene expression changes, which allow us 
to capture the early transcriptional events of each oncogene, as opposed to the 
transcriptional profile of a transformed cell. Recombinant adenoviruses were amplified 
and concentrations were determined using previously published protocols (Luo et al., 
2007). All viruses were obtained from Vector Biolabs, except RAF1 (Cell Biolabs) and 
EGFR (gift from Duke University). 
Western blot analysis for expression of growth factor proteins in HMECs and apoptotic 
proteins in breast cancer cell lines 
Proteins from HMECs and the following cell lines were extracted: HCC3153, 
HCC1395, ZR75B, HCC1569, HCC2218, SKBR3, LY2, SUM52PE, ZR7530, 
MDAMB361, AU565, BT474, BT483, CAMA1, HCC1419, HCC1428, MCF7, 
MDAMB175, T47D, ZR751, HCC1954, JIMT1, BT549, HCC1143, HCC1806, 
HCC1937, HCC38, HCC70, HS578T, and MDAMB213 (Appendix A). To collect 
protein, cells were washed with PBS, scraped on ice into PBS, pelleted by centrifugation, 
lysed in lysis buffer for 15 minutes (50 mM Tris (pH 8.0), 140 mM NaCl, 5 mM EDTA, 
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1% TritionX-100, 0.1% SDS, protease cocktail (Sigma), phosphatase inhibitors cocktails 
2 and 3 (Sigma), and centrifuged at 13,000 × g for 15 minutes. Protein quantification of 
lysates was determined using a BCA assay (Pierce). Electrophoresis was performed on a 
8–12% Tris-HCl polyacrylamide gel (BioRad) for HMEC Western blots and 18% 
Criterion TGX Tris/Glycine gels (BioRad) for apoptotic protein western blots. Proteins 
were then transferred to a PVDF membrane using the iBlot® 2 Dry Blotting System 
(Thermo Fisher Scientific). Membranes were blocked for 1 hour with SuperBlock™ 
(Thermo Fisher Scientific) and probed with the following primary antibodies: AKT 
(#9272), pAKT (#13038), BAD (#9292), EGFR (#4267), pEGFR (#2234), HER2 
(#2165), pHER2 (#2244), IGF1R (#3027), pIGF1R (#3021), KRAS (sc-30), pMEK 
(#9154), p-cRAF (#9427), GAPDH (#5174), and β-tubulin (#2146). Of note, pAKT ran 
higher than expected due to AKT myristoylation. Breast cancer cell line lysates were 
probed with the following: MCL-1 (#5453), BIM (#2933), and B-actin (#3700). All 
antibodies were obtained from Cell Signaling Technology, besides KRAS, which was 
obtained from Santa Cruz. 
Dose response assay 
Cell lines were plated at 2000 cells per well in 384 well plates for 24 hours at 
37°C. Detailed information on the cell lines and their growth conditions is provided in 
(Appendix A). All cell lines were obtained from American Type Culture Collection 
(ATCC). Drugs were diluted to six doses in media containing 5% FBS (Gibco/Life 
technologies) and 1% anti–anti (Gibco/Life technologies). Erlotinib, trametinib, UMI-77, 
obatoclax, doxorubicin, and neratinib were purchased from Selleckchem, and 
bafilomycin and AKT1/2 inhibitor were from Sigma-Aldrich. Drugs were dissolved in 
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100% DMSO and stored at -80°C. Detailed information on drug doses is provided in 
Table 3.1. Cell viability and growth was measured using CellTiter-Glo (Promega) 72 
hours post-treatment. All treatment doses were performed in four replicates. The Drug 
Discovery Core Facility, a part of the Health Sciences Cores at the University of Utah, 
performed the dose response assay. EC50s (concentration of each drug that provides half 
of the maximum response) were determined and converted to drug sensitivity values 
defined as the negative log of the EC50s (-logEC50) (Table 3.2). EC50 values were 
calculated from dose response data by plotting in GraphPad Prism 4 and using the 
equation Y = 1/(1 + 10ˆ((logEC50 − X) × HillSlope)) with a variable slope (Y min = 0 and 
Y max = 1). 
Drug Company Stock Conc. Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 
Erlotinib Selleck 30 mM 100 um 30 uM 10 uM 3 uM 1 uM 0.3 uM 
Neratinib Selleck 1 mM 1 uM 0.1 uM 0.05 uM 0.01 uM 0.005 uM 0.001 uM 
UMI-77 Selleck 30 mM 30 uM 10 uM 3 uM 1 uM 0.3 uM 0.1 uM 
Bafilomycin Sigma-Aldrich 1 mM 5 uM 1 uM 0.5 uM 0.1 uM 0.05 uM 0.01 uM 
Doxorubicin Selleck 10 mM 3 uM 1 uM 0.3 uM 0.1 uM 0.03 uM 0.01 uM 
SigmaAKT Sigma-Alrich 10 mM 10 uM 3 uM 1 uM 0.3 uM 0.1 uM 0.03 uM 
Tramatinib Selleck 100 mM 30 uM 10 uM 3 uM 1 uM 0.3 uM 0.1 uM 
Obatoclax Selleck 5 mM 2.5 uM 1 uM 0.5 uM 0.2 uM 0.1 uM 0.05 uM 
Table 3.1. Drug dose information for the drug response assay. 
Cell Line 
Bafilomycin Doxorubicin Erlotinib Neratinib UMI.77 Obatoclax Sigma 
AKT 
Inhibitor 
Tramatinib 
HCC1143 6.940 5.993 6.113 4.461 5.390 5.951 4.365 4.181 
HCC1806 8.534 6.457 6.212 5.769 4.412 6.408 4.508 4.522 
HCC1937 5.042 5.751 4.553 3.901 4.866 5.910 4.654 3.102 
BT549 7.487 6.460 NA NA 5.220 5.796 4.413 NA 
HCC38 7.896 6.213 3.692 NA 3.018 6.404 3.192 2.051 
HS578T 6.275 6.026 3.853 1.410 5.298 6.389 4.579 NA 
AU565 8.411 6.965 6.426 8.410 5.769 6.828 6.257 4.694 
HCC1569 NA 5.287 4.408 NA 5.336 5.889 4.876 2.627 
MDAMB361 8.508 6.234 4.862 5.816 5.345 6.527 7.133 5.098 
SKBR3 7.796 5.716 4.538 6.897 NA 6.047 5.000 -10.117 
BT483 7.774 6.137 3.242 NA 5.289 6.980 NA 4.200 
MCF7 8.018 5.529 NA NA NA 6.271 4.976 NA 
T47D 8.362 6.116 4.846 3.997 5.632 6.829 5.572 NA 
ZR751 6.837 4.590 NA 5.677 2.412 6.093 4.687 6.770 
BT474 8.425 5.741 NA 7.317 0.381 5.669 4.802 3.537 
CAMA1 8.178 5.848 NA 2.451 4.740 6.507 4.985 -1.851 
HCC1395 7.593 6.375 5.083 3.059 5.914 7.391 6.616 6.324 
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HCC1419 7.904 5.523 4.524 7.210 4.002 5.849 4.906 NA 
ZR7530 7.504 5.443 5.953 7.943 5.830 6.306 4.790 4.185 
HCC1954 7.527 7.308 6.422 7.594 6.127 7.041 6.313 6.838 
HCC2218 10.000 NA 4.442 10.000 4.974 6.164 4.814 10.000 
HCC70 7.529 6.440 5.503 4.709 5.188 6.229 6.257 10.000 
JIMT1 8.569 6.261 5.206 4.822 4.981 6.145 4.201 4.852 
Table 3.2. -log(EC50) drug sensitivity values from the dose response assay. All concentration are in M. NA 
indicates that an EC50 value could not be determined. 
RNA preparation and RNA sequencing 
After transfection with adenovirus and Western blot validation, cells were 
pelleted, washed in PBS, and stored in RNAlater (Ambion). Cells were then DNase 
treated, and RNA was extracted using the RNeasy kit (Qiagen). RNA replicates were 
generated for each overexpressed gene: six each for AKT, BAD, IGF1R, and RAF1; five 
for HER2; and 12 for GFP control (Gene Expression Omnibus (GEO) accession 
GSE83083). Additionally, 9 replicates of each of KRAS and GFP control were generated 
(GEO accession GSE83083). The EGFR signature and its corresponding GFP control 
were previously generated with six replicates of each (GEO accession GSE59765). RNA 
concentration was determined with a Nanodrop (ND-1000). cDNA libraries were 
prepared from extracted RNA using the Illumina Stranded TruSeq protocol (Illumina). 
cDNA libraries were sequenced at Oregon Health and Sciences University using the 
Illumina HiSeq 2000 sequencing platform with six samples per lane. Single-end reads of 
101 base pairs were generated. 
Gene expression data processing, normalization, and datasets 
The Rsubread R package (version 1.14.2) was used to align and summarize RNA-
Seq reads to the UCSC hg19 reference genome and annotations (Liao, Smyth & Shi, 
2014, Liao, Smyth & Shi, 2013). All RNA-Seq data in this study, including HMEC 
overexpression data (GSE83083, GSE59765), TCGA breast cancer data (GSE62944), 
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and ICBP breast cancer RNA-Seq dataset (GSE48213), were processed and normalized 
using a pipeline that can be found at https://github.com/srp33/TCGA_RNASeq_Clinical 
(McCubrey et al., 2007, Johnson, Li & Rabinovic, 2007). 
Generation of gene expression signatures 
 
Figure 3.3. Gene expression signatures for key GFRN pathways generated by ASSIGN. a. AKT 20 gene signature, 
b. BAD 250 gene signature, c. EGFR 50 gene signature, d. HER2 10 gene signature, e. IGF1R 100 gene signature, f. 
KRAS (G12V) 200 gene signature, and g. RAF1 350 gene signature. The horizontal black bar indicates green 
fluorescent protein (GFP) overexpressing control samples, and the red bar indicates the overexpressed genes of interest 
(i.e., AKT1, BAD, EGFR, ERBB2 (HER2), IGF1R, KRAS (G12V), and RAF1, respectively) signature samples. 
Adaptive Signature Selection and InteGratioN (ASSIGN; version 1.9.1), a semi-
supervised pathway profiling toolkit, was used to generate gene expression signatures. A 
formal definition of the ASSIGN model and software implementation was reported 
previously (Shen et al., 2015). RNA-Seq data from HMECs overexpressing GFP control 
were compared to HMECs overexpressing AKT1, IGF1R, BAD, HER2, KRAS (G12V), 
RAF1, and EGFR. ASSIGN uses a Bayesian variable approach to select genes with the 
  
51 
highest weights and signal strengths, indicating differential expression. These genes 
represent oncogenic signatures (Figure 3.3). 
Gene set enrichment analysis on RNA-Seq signatures 
The R package Gene Set Variation Analysis for microarray and RNA-Seq data 
(GSVA; version 1.22.0), a non-parametric, unsupervised method for estimating variation 
of gene set enrichments in gene expression data, was used to perform this gene set 
enrichment analysis (Hänzelmann, Castelo & Guinney, 2013). GSVA was downloaded 
from Bioconductor (3.4) (Huber et al., 2015). RNA-Seq data from HMECs 
overexpressing GFP (control), AKT1, IGF1R, BAD, HER2, KRAS (G12V), RAF1, and 
EGFR was used as input for the GSVA algorithm. The following gene sets were used and 
downloaded from the Molecular Signatures Database (Liberzon et al., 2011). 1,320 gene 
sets from the C2: canonical pathways collection (c2.cp.v5.2.symbols.gmt) and 50 gene 
sets from the hallmarks collection (h.all.v5.2.symbols.gmt). The following GSVA 
parameters were used: minimum gene set size = 10, maximum gene set size = 500, 
verbose = TRUE, rnaseq = TRUE, and method = “ssgsea”. GSVA returns a matrix 
containing enrichment scores for each sample and gene. The R package limma (version 
3.30.2) was used to perform a differential expression analysis between each 
overexpressed gene sample and its respective GFP control sample (Ritchie et al., 2015). 
The full results from the gene set enrichment analysis can be found in (Rahman et al., 
2017). 
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Batch adjustment and estimation of pathway activity in ICBP and TCGA BRCA patient 
samples 
HMEC oncogenic signatures (training data) were applied to 55 ICBP breast 
cancer cells and 1,119 TCGA breast cancer patient gene expression datasets (test data) to 
estimate pathway activation status. To avoid confounding batch effects within and 
between the training and test data, the data were adjusted for batch effects. First, in order 
to visualize batch effects in the data a principal component analysis (PCA) was 
performed on the training (HMEC overexpression RNA-Seq) data. The training data were 
sequenced separately in three batches, and significant batch effects were observed. Batch 
effects were adjusted using the ComBat function from the R package sva (version 3.21.1) 
(Johnson, Li & Rabinovic, 2007, Leek et al., 2012). ComBat was run using the reference-
batch option, which adjusts the data to match an indicated batch. The sequencing batch 
containing AKT1, IGF1R, BAD, HER2, and RAF1 was selected as the reference batch. A 
model-matrix indicating which pathway was associated with each training replicate was 
also included. After the first batch adjustment, PCA was performed on the adjusted 
training data and the test data (ICBP breast cancer cell lines or TCGA breast tumors). 
Significant batch effects were identified between the training and test data and performed 
a second round of ComBat adjustment, using the training data as the reference batch. 
After the second batch adjustment, PCA was performed to confirm the resolution of the 
batch effect. Additionally, background baseline gene expression differences were 
adjusted between oncogenic signatures and test samples (ICBP cell lines and TCGA 
patient data) using ASSIGN’s adaptive background parameter. The variation in 
magnitude and direction of signature-relevant gene expression between oncogenic 
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signature training samples and test samples was adjusted using ASSIGN’s adaptive 
signature parameter. The model specification options for all analyses are listed in Table 
3.3. Default ASSIGN settings were used for all other parameters. 
Parameter Value 
adaptive_B TRUE 
adaptive_S TRUE 
mixture_beta FALSE 
S_zeroPrior FALSE 
sigma_sZero 0.05 
sigma_sNonZero 0.5 
iter 100,000 
burn_in 50,000 
Table 3.3. ASSIGN parameters used for all analyses. The default values were used for all other parameters. 
Optimization of single-pathway estimates in ICBP cell line and TCGA BRCA patient data 
To determine the optimum number of genes for each oncogenic signature, 
signatures with gene list lengths from 25 to 500 genes, in 25 gene increments, were 
generated using ASSIGN’s single pathway settings. By default, ASSIGN chooses gene 
lists that contain an equal number of genes that have increased or decreased expression 
with pathway activation. ASSIGN also allows a specific gene to be anchored in the 
signature, making sure that the gene is always included in the signature, even if it is not 
chosen during gene selection or if it is removed from the signature after Monte Carlo 
simulation. Anchor genes were chosen based on the oncogene overexpressed in each 
signature. Pathway predictions generated by ASSIGN are represented as values from zero 
to one. Values of zero represent no pathway activity and values of one represent high 
pathway activity. For all the signatures that passed internal leave-one-out cross-
validation, pathway estimates were included for further validation in proteomics, 
mutation, and gene expression. To determine optimal signature gene list lengths and 
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evaluate the robustness of the generated signatures, pathway activation estimates from 
ICBP and TCGA were correlated with proteins that reflect downstream pathway 
activation from corresponding ICBP and TCGA RPPA data as a measurement of protein 
quantity (Hennessy et al., 2010, Paweletz et al., 2001).  
 
Figure 3.4. GFRN gene expression signature validations in TCGA breast cancer data. Pathway activity estimate 
boxplots between the a. AKT pathway and b. BAD pathway between PI3KCA mutated and PI3KCA wild-type TCGA 
breast cancer samples (n=787). Any mutation in PI3KCA was considered pathogenic in this mutation analysis. c. HER2 
pathway activation estimates between HER+ and HER- patient TCGA samples (n=708). Pathway activation estimates 
for d. IGF1R, e. AKT, f. EGFR, and g. RAF1 between ‘high’, ‘intermediate’, and ‘low’ expressing samples in 1,119 
BRCA TCGA samples. Samples with 90 percentile or higher expression were considered ‘high’, 10 percentile or lower 
were considered ‘low’, and 10 to 90 percentile were considered ‘Intermediate’ expressing samples for AKT1, EGFR 
and RAF1. For IGF1R validation, samples with 80 percentile or higher IGF1R expression were considered ‘high’, 20 
percentile or lower was considered ‘low’, and 20 to 80 percentile expression were considered ‘Intermediate’ expressing 
samples. 
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Significant correlations were found between pathway activation estimates for all GFRN 
signatures and appropriate downstream pathway proteins (Farabaugh, Boone & Lee, 
2015, Corbit et al., 2003, Kolch et al., 1993, Matallanas et al., 2011) (Table 3.4). 
Mutation-based analysis was performed using t-tests between patient groups based on 
mutation status in oncogenic proteins. For example, TCGA mutation data were analyzed 
and higher AKT activation and lower BAD activation estimates were found in patients 
with PI3KCA mutations (Figure 3.4a, b) and higher HER2 pathway activation estimates 
were found in HER2-positive tumors (Figure 3.4c). In gene expression data, higher 
pathway activity for AKT, EGFR, IGF1R, and RAF1 in TCGA samples classified as 
“high” expressing using percentiles from TCGA RNA-Seq dataset for their respective 
genes AKT1, EGFR, IGF1R, and RAF1 were found (Figure 3.4d–g). Samples with 90th 
percentile or higher expression were considered “high”, 10th percentile or lower “low”, 
and 10th to 90th percentile “intermediate” expressing samples for AKT1, EGFR, and 
RAF1. For IGF1R validation, samples with 80th percentile or higher IGF1R expression 
were considered “high”, 20th percentile or lower “low”, and 20th to 80th percentile 
“intermediate” expressing samples. Finally, pairwise Spearman correlation values and 
calculated p-values between pathway predictions and corresponding TCGA reverse phase 
protein array (RPPA) data were used to determine which gene numbers gave the best 
correlations. The HER2 and AKT signatures performed better with fewer genes. 
Therefore, 5, 10, 15, and 20 gene signatures for HER2 and AKT were generated. 
Significant correlations were seen between pathway estimates and RPPA protein scores. 
For example, AKT pathway activation estimates were significantly correlated with AKT, 
PDK1, and phosphorylated-PDK1 protein levels in both ICBP and TCGA (p-values < 
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0.0001) samples. Due to the lack of proteins available to validate the BAD signature, 
negative correlations between BAD pathway estimates and AKT protein based on the 
knowledge that activation of AKT leads to BAD inhibition were used (Datta et al., 1997). 
The optimized gene list was the list that gave the best average correlation in the expected 
direction for the RPPA data correlated with each pathway in TCGA data and was 
significant both in ICBP and TCGA data, with an ICBP correlation of at least 0.3 and a 
maximum gene list length of 300 genes. Appendix B includes a gene list of optimum 
gene numbers determined for each signature. Scaled ASSIGN pathway activity 
predictions for each of the seven optimized pathways in TCGA and ICBP are available in 
(Rahman et al., 2017). 
Pathway Number of Genes Protein 
ICBP TCGA 
Cor. p-value Cor. p-value 
ATK 20 
Akt 0.576 2.03E-04 0.192 1.54E-07 
PDK1 0.574 2.14E-04 0.239 5.93E-11 
PDK1_pS241 0.535 6.50E-04 0.339 5.74E-21 
BAD 250 
Akt -0.456 4.33E-03 -0.150 4.43E-05 
PDK1 -0.605 8.14E-05 -0.313 4.37E-18 
PDK1_pS241 -0.518 1.02E-03 -0.232 2.23E-10 
EGFR 50 
EGFR 0.470 0.050 0.357 2.09E-23 
EGFR_pY1068 0.397 0.028 0.129 4.50E-04 
EGFR_pY1173 NA NA 0.155 2.44E-05 
HER2 10 
HER2 0.923 0.00E+00 0.376 1.61E-05 
HER2_pY1248 0.953 0.00E+00 0.356 1.37E-04 
IGF1R 100 
IRS1 NA NA 0.324 2.37E-19 
IGF1R 0.086 0.608 NA NA 
PDK1 0.569 2.45E-04 0.371 2.68E-25 
PDK1_pS241 0.509 1.26E-03 0.403 5.33E-30 
KRAS 
(G12V) 200 
EGFR 0.423 8.57E-03 0.493 4.05E-46 
EGFR_pY1068 0.296 7.17E-02 0.089 1.60E-02 
EGFR_pY1173 NA NA 0.090 1.47E-02 
MEK1 NA NA 0.116 1.69E-03 
RAF 350 
MEK1 0.285 0.084 0.245 1.72E-11 
PKC.alpha 0.467 3.46E-03 0.396 6.36E-29 
PKC.alpha_pS657 0.462 3.83E-03 0.415 0.00E+00 
Table 3.4. Spearman correlations for protein correlations. Spearman correlations between pathway activation 
estimates and proteomics data for optimum selection in ICBP cell line and TCGA proteomics data. NA indicates that 
the value is not available. 
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Software implementation of pathway activity prediction with generated signatures 
The signatures presented here have been included in the latest version of the 
ASSIGN package (version 1.11.3) so that pathway activity prediction can be easily 
performed on other datasets. Because the gene list length can affect the results of 
ASSIGN analysis, the signatures can be used in their original form, or the gene list 
lengths can be optimized based on maximizing correlations between ASSIGN activity 
predictions and a set of variables, such as RPPA data. 
Determination of growth factor phenotypes in ICBP and TCGA 
Cell lines from ICBP, patient tumors from TCGA, and breast cancer cell lines for 
in vitro experiments were classified as either the survival or growth phenotype by 
calculating the mean of scaled pathway activation values for HER, IGF1R, and AKT for 
the survival phenotype and the mean of scaled pathway activation values for BAD, 
EGFR, KRAS, and RAF1 for the growth phenotype. Each sample was classified as either 
survival or growth phenotype based on which phenotype had the highest mean. 
Identification of additional drug response heterogeneity within growth factor phenotypes 
To classify samples into subgroups within the growth factor phenotypes that 
corresponded to high and low HER2 activity within the survival phenotype and high and 
low BAD activity within the growth phenotype, the R function kmeans was used to 
perform k-means clustering on the scaled pathway activity data for AKT, HER2, BAD, 
and EGFR pathways with four means and 100 random starts. After classifying samples, t-
tests were performed using the R function t.test on known HER2/AKT/PI3k/mTOR 
targeting drugs and EGFR/MEK targeting drugs from the drug response assay described 
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above between the cell lines identified as AKT/HER2 high and AKT/HER2 low, and 
between the cell lines identified as EGFR/BAD high and EGFR/BAD low. P-values were 
corrected using an FDR correction and identified drugs that showed a significantly 
different drug response among the growth factor subgroups. When determining how 
growth phenotypes and ER, PR, and HER2 status performed in assessing drug response, 
mean drug response across all available cell lines as the cutoff were used. Cell line drug 
sensitivity value above this cutoff was considered as “sensitive” and otherwise 
“resistant”. 
Statistical analyses 
The prcomp function from the stats R package was used to compute the principal 
components in TCGA breast cancer patient RNA-Seq data. The Spearman rank-based 
pairwise correlation method was used for all principal component-based correlations, 
pathway predictions, and protein correlations. The cor.test function from the stats R 
package was used to calculate p-values for each correlation (Hollander, Wolfe & 
Chicken, 2013, Best, Roberts, 1975). Student’s t-tests were used to find the differences in 
principal component values based on IHC-based subtypes and mutation status within 
GFRN phenotypes; pathway activity based on mutation status and drug; sensitivity 
differences based on pathway activity, and gene expression boxplots. The heatmap.2 
function from the ggplots R package and the Heatmap function from the 
ComplexHeatmap R package were used for generating pathway activity and pathway 
activity–drug response correlation heatmaps (Wickham, 2010, Gu, Eils & Schlesner, 
2016). The lm function from the stats R package was used to model principal component 
values in TCGA using clinical subtypes, intrinsic subtypes, and GFRN subgroups to 
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determine R2 values. Models were compared using the anova function from the stats 
package to determine significance of adding additional features to the models. All 
analyses were conducted in R and the code is available at 
https://github.com/mumtahena/GFRN_signatures (The R Core Team, 2014). 
Results 
Two dominant phenotypes in breast cancer patients and cell lines 
 Gene expression signatures were developed and validated for the following 
GFRN pathways: AKT, BAD, EGFR, HER2, IGF1R, KRAS (G12V mutation), and 
RAF1. Signatures were generated in normal human mammary epithelial cells (HMECs) 
by expressing these genes using recombinant adenoviruses. The control samples received 
green fluorescent protein (GFP) adenovirus. The overall goal of this approach was to 
capture the downstream transcriptional events specific for each expressed GFRN gene, or 
the gene expression signatures, and to use these signatures to estimate pathway activity in 
cell lines and patient samples. To determine if adenovirus infection led to pathway 
activation for each overexpressed gene, protein levels of gene products and their 
downstream targets were measured the using western blotting (Figure 3.2). Next, RNA-
Seq was performed on multiple replicates of HMECs overexpressing GFRN genes and 
GFP controls. These data were used to generate pathway-based gene expression 
signatures for each overexpressed gene using the previously published ASSIGN pathway 
profiling approach (Figure 3.3) (Shen et al., 2015). Briefly, ASSIGN prioritized genes 
that best discriminated GFP control samples from samples overexpressing GFRN genes 
to generate gene expression signatures. Next, ASSIGN was used to estimate the 
activation of each GFRN member (AKT, BAD, EGFR, HER2, IGF1R, KRAS (G12V), 
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and RAF1) in 1,119 breast cancer patient samples from TCGA and 55 samples from the 
ICBP panel of breast cancer cell lines. ASSIGN was used to measure highly correlated 
GFRN pathway activity more accurately in patient samples with signatures generated in 
HMECs since ASSIGN estimates correlated pathway activities robustly by adapting 
pathway signatures into specific disease context. The robustness of each pathway 
signature was validated with (1) leave-one-out cross-validation (LOOCV), (2) relevant 
reverse phase protein array (RPPA) scores, (3) gene expression data for the 
overexpressed oncogenes, and (4) mutation data (Figure 3.4). After validating the GFRN 
signatures, gene set enrichment analysis was performed to identify enriched signaling 
patterns within each signature (Rahman et al., 2017). 
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Figure 3.5. Analysis of pathway activity and intrinsic subtypes. in a. 1,119 TCGA breast cancer samples and b. 55 
ICBP breast cancer cell lines. HER2, IGF1R, and AKT and BAD, EGFR, KRAS (G12V), and RAF1 pathway activities 
reveal two distinct clusters that were negatively associated. GFRN characterization reveals a dichotomy in TCGA 
breast cancer patients, high BAD/EGFR/KRAS/RAF1 (growth phenotype; column color label shown in aquamarine) 
and high HER2/IGF1R/AKT (survival phenotype; column color label shown in coral). Subtypes determined by 
immunohistochemistry and intrinsic subtyping are shown on the right side row color labels. c. K-means clustering of 
TCGA samples identifies subsets of samples within the survival phenotype that have high HER2 activation and low 
HER2 activation, and subsets of samples within the growth phenotype that have high BAD activation and low BAD 
activation (shown in the left side row color labels). d. These clusters are also seen in ICBP 
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Figure 3.6. Pathway activity estimates between ER+ and ER- samples in breast cancer cell lines and patient 
data. a. 19 ER- breast cancer cell lines from ICBP, b. 32 ER+ breast cancer cell lines from ICBP. c. 230 ER- breast 
cancer patient samples from TCGA, and d. 785 ER+ breast cancer patient samples from TCGA. The growth phenotype 
is represented in aquamarine above the heat map, and the survival phenotype in coral. Subtypes determined by 
immunohistochemistry (ER, PR, and HER2), intrinsic subtyping, and PAM50, are label in the right side of the 
heatmap. 
Finally, unsupervised hierarchical clustering of the pathway activity estimates for 
all GFRN signatures in both ICBP cell lines and TCGA patient data resulted in a 
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dichotomous pattern (Figure 3.5a, b). The HER2, IGF1R, and AKT pathways formed a 
cluster, as did the remaining BAD, EGFR, KRAS, and RAF1 pathways (Figure 3.5a, b). 
There was some overlap between the two clusters, likely due to the known crosstalk and 
compensation that occurs between the PI3K and MAPK pathways (Mendoza, Er & 
Blenis, 2011). In general, however, when one set of pathways was high, the other set was 
low, which shows that samples expressed a dominant phenotype of GFRN activity. These 
results strongly suggest a pathway-level dichotomization of the GFRN, which is 
represented by two primary phenotypes: (1) activation of the HER2/IGF1R/AKT 
pathways or “survival phenotype”; (2) activation of the BAD/EGFR/KRAS/RAF1 
pathways or “growth phenotype.” 
 
Figure 3.7. Pathway activation estimates across clinical subtypes. (IHC-based, N=1012) in TCGA breast cancer 
data for a. the AKT pathway b. the BAD pathway c. the HER2 pathway d. the IGF1R pathway e. the EGFR pathway f. 
the RAF1 pathway g. the KRAS pathway. 
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Figure 3.8. Pathway activation estimates across intrinsic subtypes. (PAM50 based, N=510) in TCGA breast cancer 
data for a. the AKT pathway b. the BAD pathway c. the EGFR pathway d. the HER2 pathway e. the IGF1R pathway f. 
the KRAS pathway g. the RAF1 pathway estimates. 
After identifying the two main dichotomous GFRN phenotypes, these phenotypes 
were investigated for how they related to classic IHC-based subtypes, intrinsic subtypes, 
and additional heterogeneity present within each phenotype (Figure 3.5). To investigate if 
these phenotypes were independent of ER status, pathway activity estimates were 
clustered for ER+ and ER- samples separately for both ICBP and TCGA samples. The 
pathway activity bifurcation pattern, as represented by GFRN phenotypes, was consistent 
within ER+ and ER- samples, indicating GFRN phenotypes are partially independent of 
ER status (Figure 3.6). The variability between histological and intrinsic subtypes can 
also been seen in the heatmap sidebars for TCGA and ICBP data (Figure 3.5a–d), and in 
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boxplots of pathway activity estimates across clinical and intrinsic subtypes in TCGA 
(Figure 3.7 and Figure 3.8). Samples classified as the survival phenotype included 
samples from all histological and intrinsic subtypes. Of the 596 TCGA tumors from the 
survival phenotype, 84.74% were ER+, 72.99% were PR+, 18.12% were HER2+, and 
26.51%, 17.79%, 6.88%, and 0.34% were of luminal A, luminal B, HER2-enriched, and 
basal subtypes, respectively. For the growth phenotype (n = 523), even more 
heterogeneity in ER, PR, and HER2 status was observed (ER+, 53.54%; ER-, 37.67%; 
PR+, 46.85%; PR-, 43.98%; HER2+, 10.33%; HER2-, 56.41%; basal, 17.78%; Her2 
enriched, 3.06%; luminal A, 13.96%; and luminal B, 4.02%). Hence, clinical and intrinsic 
subtypes varied in each phenotype cluster, and the GFRN phenotypes provide additional 
information which complements existing breast cancer clinical and intrinsic subtypes in 
both patient and cell line data (Perou, 2010, Sørlie et al., 2001, Sotiriou et al., 2003, 
Perou, C. M. et al., 2000). 
HER2 activity differences were also observed within the survival phenotype, and 
differences in BAD activity within the growth phenotype. To further classify samples 
specifically on these differences, k-means clustering was performed on the AKT, BAD, 
EGFR, and HER2 pathway activity predictions in ICBP and TCGA. The four resulting 
clusters separated the survival phenotype into two subsets of samples that had either high 
or low HER2 activity, and the growth phenotype into two subsets of samples that had 
either high or low BAD activity. These patterns were observed in both TCGA and ICBP 
datasets (Figure 3.5c, d). Again, subtype plotted against these four subgroups as 
presented in the sidebars reveal there is additional heterogeneity within ER and PR status 
that is captured using GFRN subgroups. Of note, a survival analysis of the four 
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subgroups in TCGA did not show significant differences in survival (λ2 = 5.5, p-
value = 0.141; Figure 3.9). This indicates that these subgroups may not relate to survival 
directly. Instead, these subgroups discriminate aberrant pathway activity that may help 
select patient subgroups likely to respond to specific drugs targeting those pathways. 
GFRN phenotypes complement ER status and current subtyping methods, but are more 
biologically focused than current intrinsic subtypes and are useful in addition to current 
IHC-based subtypes. 
 
Figure 3.9. Survival analysis of the four subgroups in TCGA BRCA samples (N=1,119). (Kaplan-Meier survival 
analysis for the four identified subgroups using the Peto and Peto modification of Gehan-Wilcoxon test did not show 
significant differences across the subgroups (λ2=5.5, p=0.141). 
GFRN phenotypes and subgroups contribute to variation found in TCGA breast cancer 
gene expression data 
In order to determine if the GFRN phenotypes and subgroups contributed to 
heterogeneity in the breast cancer data using an unbiased approach, an unsupervised PCA 
was performed on 1,119 breast cancer RNA-Seq samples from TCGA. PCA is a 
dimension reduction method capable of identifying uncorrelated sources of variation 
within a dataset as principal components (PCs) (Pearson, 1901, Hotelling, 1933). The 
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first five PCs identified in this dataset represented the most significant amount of 
variability explaining 34.3% of the total variance. The remaining components, each 
accounting for less than 4% of the total variation, were not investigated due to their minor 
contribution to total variance. Of note, PC 1 was significantly associated with average 
gene expression of the samples (Spearman’s correlation -0.786, p-value < 0.0001), 
potentially reflecting technical and non-disease-related sample variation (Figure 3.10). 
However, PC 1 was included in analyses to demonstrate its performance. To explain 
variability as presented by PC values, currently used histological (ER, PR, and HER2) 
and intrinsic subtypes were compared to GFRN-based approaches. First, each 
classification approach was investigated if it explained variability in each PC. When 
comparing PC values, significant differences were found between ER+ and ER- samples 
and PR+ and PR- samples for PCs 1 through 5, between HER2+ and HER2- samples for 
PCs 3, 4, and 5, across intrinsic subtypes for PCs 1 through 5 (ANOVA, p-value < 
0.0001), between growth and survival phenotypes for PCs 2 through 5, and across four 
GFRN subgroups for PCs 1 through 5 (ANOVA p-value < 0.0001). These results indicate 
that significant variation underlying TCGA breast cancer data may be contributed from 
multiple sources, including GFRN phenotypes, subgroups, and histological and intrinsic 
subtypes. 
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Figure 3.10. Correlation between mean gene expression values for all samples and PC 1 values from breast cancer 
(BRCA) TCGA RNA sequencing samples (Spearman’s correlations: -0.786, p-value < 0.0001. 
Second, a linear modeling approach was used to model the first five PCs with 
GFRN subgroups, intrinsic subtypes (PAM50), and histological (ER, PR, and HER2) 
subtypes. Variance explained by each model was compared in terms of R2 values. We 
included 355 TCGA tumor samples for which all of these variables were available. ER 
(R2 = 0.56) and PR (R2 = 0.407) status explained a significant proportion of PC 2 but 
explained less than 10% of the total variability in the other PCs. HER2 status alone 
explained less than 4% of the variability for any of the PCs. Both GFRN subgroups, and 
intrinsic subtypes, explained additional variability in PCs 1–5. For all five PCs, adding 
the GFRN subgroups or intrinsic subtypes to clinical subtypes increased the R2 values of 
the model (p-value < 0.01 for all models tested). Specifically, adding GFRN subtypes to a 
model of PCs explained an additional 10–35% (p-value < 0.00001) of the variation when 
compared to a model of ER status alone while PAM50 explained only 4–20% of the 
variation. 
On a more granular level, GFRN subgroups explained an additional 13.5% (p-
value < 0.00001) of the variability for PC 2, which was not explained by ER status alone. 
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For PC 3, GFRN subtypes explained an additional 35% of the variation when compared 
to a model of ER status alone (ER R2, 0.052; ER+ GFRN subtype R2, 0.398; p-value < 
0.00001) and intrinsic subtypes only explained an additional 20% of the variation 
compared to the same model of ER status alone (ER+ intrinsic subtype R2, 0.254; p-value 
< 0.00001). Overall, the models that contained GFRN subgroups explained a larger 
percentage of the variance of PC 1, 3, and 4, and models that contained intrinsic 
subgroups explained a larger percentage of the variance of PCs 2 and 5. These significant 
R2 and p-values confirm the non-redundancy of GFRN subgroups in relation to 
commonly used clinical features in breast cancer. Additionally, GFRN subgroups explain 
additional variance in models of PCs 1, 3, and 4 compared to models containing intrinsic 
subgroups. 
 
Figure 3.11. Principal component analysis across TCGA breast tumors. Correlation heatmap between principal 
component (PC) values from PCs 1 through 5 and ASSIGN GFRN pathway estimates from TCGA breast cancer RNA-
Seq data. Red colors represent a positive correlation and blue colors represent a negative correlation. 
Next, the variability contributed by GFRN subgroups was investigated in relation 
to biological signals, or pathway activity in this case. PC values for PCs 1 through 5 were 
correlated with the GFRN pathway activation estimates from TCGA (Figure 3.11). 
Again, a striking bifurcated pattern was found in the correlations between pathway 
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activity and PCs in this independent variability analysis. PC 2 was positively correlated 
with EGFR, KRAS, RAF1, and BAD activation and negatively correlated with HER2, 
IGF1R, and AKT activation. Therefore, PC 2 is demonstrating characters of the growth 
phenotype. PCs 3 and 4 were positively correlated with HER2, IGF1R, and AKT 
activation and negatively correlated with EGFR, KRAS, RAF1, and BAD activation, thus 
representing growth phenotype characteristics (Figure 3.11). Both PC 1 and PC 5 were 
negatively correlated with EGFR and RAF1 activation but positively correlated with 
BAD activation. Since intrinsic subtypes are derived empirically without pointing to any 
specific biological phenomenon, a correlation to intrinsic subtypes could not be 
performed. 
In summary, these novel GFRN subgroups explained a significant amount of 
variability in TCGA RNA-Seq data. The GFRN subgroups described variation beyond 
ER, PR, and HER2 status in all cases, and beyond intrinsic subtypes for three out of five 
cases. These results suggest that variability in breast cancer data can be further explained 
in terms of the GFRN pathway activity. Therefore, GFRN subgroups can augment current 
breast cancer subtyping methods by encompassing additional heterogeneity not captured 
by traditional approaches. This pathway-based approach may further explain specific 
variation in terms of pathway activity, which may point to identifying therapeutic targets. 
Breast cancer growth phenotypes bifurcate in expression of mitochondrial apoptotic 
proteins 
Next, differences between the survival and growth phenotypes were examined at 
the biological level, specifically in terms of mitochondrial-mediated intrinsic apoptosis 
mechanisms. Although cytotoxic anticancer agents induce cell death through various 
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mechanisms, including intrinsic or extrinsic apoptosis, necrosis, autophagy, or mitotic 
catastrophe (Ricci, Zong, 2006, Fulda, Debatin, 2006), we focused on mitochondrial-
mediated intrinsic apoptosis mediated by BCL-2 family proteins for the following 
reasons. First, BCL-2 family members, which regulate the commitment to mitochondrial 
apoptosis by balancing pro-apoptotic proteins such as BAD and BIM, and anti-apoptotic 
proteins such as BCL-2 or MCL-1 (Czabotar et al., 2014), have been shown to contribute 
to the formation, progression, and therapeutic response in breast and other cancers (Vo, 
Letai, 2010, Williams, Cook, 2015). 
Second, particular GFRN signaling pathways, such as those found in the survival 
and growth phenotypes, have the potential to induce apoptosis resistance by 
dysregulating BCL-2 family proteins, suggesting that targeting GFRN members may lead 
to increased apoptosis (Datta et al., 1997, Franke et al., 2003, Townsend et al., 1998, 
Carpenter, Lo, 2013, Weston et al., 2003, Ley et al., 2003, Deng et al., 2007, Nalluri et 
al., 2015, Boucher et al., 2000, Booy, Henson & Gibson, 2011). Third, several 
therapeutic strategies targeting anti-apoptotic BCL-2 family members are currently under 
investigation; therefore, understanding which BCL-2 proteins each phenotype is 
expressing may provide insight into additional treatment strategies for breast cancer 
(Letai, 2008, Montero et al., 2015, Vogler, 2014, Hassan et al., 2014). 
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Figure 3.12. Survival and growth phenotypes differ in cell survival mechanisms. a. The heatmap represents scaled 
activation values across 20 breast cancer cell lines used in this analysis for each GFRN pathway. b. Western blot 
analysis for MCL-1, BIM, and B-actin control across 20 breast cancer cell lines of either the survival phenotype or 
growth phenotype. c., d. Boxplots between samples classified as the survival phenotype or growth phenotype for c 
MCL-1 gene expression (log2 (Transcript per million)) in TCGA data, d BIM gene expression (log2 (Transcript per 
million)) in TCGA and ICBP data, and protein expression (RPPA score) in TCGA data. Student t-tests were performed 
to determine significance. 
Here, Western blotting was used to investigate whether protein expression of 
particular BCL-2 family members differed in breast cancer cell lines classified as the 
survival or growth phenotypes (Figure 3.12). The pro-apoptotic protein BIM and anti-
apoptotic protein MCL-1 were probed across ten breast cancer cell lines of the survival 
phenotype (eight ER+, two ER-), and ten cell lines of the growth phenotype (ten ER-) 
(Appendix A). Higher levels of MCL-1 were found in cell lines of the growth phenotype, 
and higher levels of BIM were found in the survival phenotype (Figure 3.12b). To 
(A) (B)
Survival Phenotype
Growth Phenotype
(C) (D)
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determine if differences in MCL-1 and BIM protein expression between the survival and 
growth phenotypes were due to other properties, such as ER status, a Western blot assay 
was performed using cell lines with additional heterogeneity in ER status. Although 
limited by the number of ER+ cell lines of the growth phenotype, 12 cell lines belonging 
to the survival phenotype (five novel ER+, three ER+ repeats from previous assay, and 
four novel ER-) and seven cell lines from the growth phenotype (one novel ER+, two 
novel ER-, and four ER- repeats) were included. The protein expression of MCL-1 and 
BIM were not strictly dependent on the ER status (Figure 3.13). 
 
Figure 3.13. Independent western blot assay for MCL-1 and BIM proteins between breast cancer cell lines from 
the survival and growth phenotypes. Lysates from 12 cell lines from the survival phenotype (8 ER+ and 4 ER-) and 7 
cell lines from the growth phenotype (1 ER+ and 6 ER-) were probed for anti- and pro-apoptotic proteins, MCL-1 and 
BIM, and compared to β-actin (loading control). 
To understand if similar results could be found in patient tumors, the expression 
of BCL-2 family member genes was examined, and MCL-1 gene expression was found to 
be higher in the growth phenotype of TCGA patient tumors (n = 523) versus the survival 
phenotype (n = 596, p < 0.0001) (Figure 3.12c). These results were consistent with 
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previous studies showing that EGFR signaling can upregulate gene expression of MCL-1 
(Townsend et al., 1998, Nalluri et al., 2015, Boucher et al., 2000, Booy, Henson & 
Gibson, 2011). In addition to MCL-1 dysregulation, breast cancer cell lines of the growth 
phenotype expressed lower levels of the pro-apoptotic protein BIM (Figure 3.12d). In 
support of this assessment, lower levels of BIM (BCL2L11) gene expression were found 
in ICBP breast cancer cell lines (p = 0.0004) and TCGA tumors (p = 0.0002), and RPPA 
protein expression was lower in TCGA tumors (p < 0.0001) (Figure 3.12d). These results 
concur with literature showing that EGFR signaling through ERK activation can lead to 
repression of BIM (Weston et al., 2003, Ley et al., 2003, Deng et al., 2007). Also, the co-
occurrence of high MCL-1 levels and low BIM levels in the growth phenotype are likely 
due to MCL-1’s known ability to bind and neutralize BIM, which leads to prevention of 
apoptosis death effector activation (Vo, Letai, 2010, Wuillème-Toumi et al., 2007). In 
summary, these results show an interesting mitochondrial apoptotic pathway induction 
that is dependent on GFRN activity. Specifically, breast tumors classified as the growth 
phenotype may overexpress MCL-1 and inhibit BIM expression to achieve cell survival. 
These findings illustrate that breast cancer phenotypes, defined by activation of specific 
growth factor receptor pathways, express different apoptotic proteins and may resist 
apoptosis differently. 
GFRNs predict drug response in breast cancer 
Since there was a clear dichotomy in the GFRN signaling mechanisms between 
the survival and growth phenotypes, these phenotypes were investigated in relation to 
drug response in breast cancer cell lines. Pathway activation estimates were correlated 
with drug response data for 90 drugs from the ICBP breast cancer cell line panel. 
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Importantly, a consistent bifurcation pattern was observed for drug response in the cell 
line data that matched the observed pathway-level bifurcation. Specifically, cancer cells 
classified as expressing the survival phenotype were sensitive to therapies that target 
AKT, PI3K, HER2, and mTOR (Figure 3.14a). Additionally, these cell lines were more 
resistant to chemotherapies and targeted therapies that block EGFR and MEK. In 
contrast, cancer cells expressing the growth phenotype were sensitive to 
chemotherapeutics such as docetaxel, paclitaxel, and cisplatin. These cell lines were also 
sensitive to EGFR- and MEK-targeted therapies, but more resistant to AKT, PI3K, 
HER2, and mTOR inhibitors (Figure 3.14a). 
 
Figure 3.14. Growth factor receptor network phenotypes reflect dichotomous drug response in breast cancer cell 
lines. Colors correspond to scaled Spearman correlations between specific pathway activation estimates generated with 
ASSIGN and drug sensitivity (-logGI50) across a. 55 breast cancer cell lines from the ICBP panel and b. 23 breast 
cancer cell lines in an independent drug assay. Red represents positive correlation and blue represents negative 
correlation. Pathways cluster across the x-axis as AKT growth phenotype (coral color) and EGFR growth phenotype 
(green). Drug classes are represented along the y-axis: pink, HER2/AKT/PI3K/mTOR-targeted therapies; yellow, 
chemotherapies/BCL-2 targeting therapies; and blue, EGFR/MEK-targeted therapies. 
This dichotomy in drug response of the survival and growth phenotypes was 
further tested in an independent drug response assay. Eight drugs on a panel of 23 breast 
cancer cell lines were tested, and cell viability was tested upon drug treatment by 
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measuring ATP levels. Drugs included were obatoclax (BCL-2, BCL-XL, BCL-W, BAK 
inhibitor), UMI-77 (selective MCL-1 inhibitor), erlotinib (EGFR inhibitor), doxorubicin 
(topoisomerase II inhibitor), trametinib (MEK inhibitor), neratinib (pan-HER tyrosine 
kinase inhibitor), Sigma-Aldrich AKT1/2 inhibitor (dual AKT1/2 inhibitor), and 
bafilomycin (apoptosis inducer that inhibits PI3K/AKT signaling and autophagy 
inhibitor) at different doses (Table 3.1). Again, a discrete pattern was observed between 
the survival and growth phenotypes that translated to a bifurcated drug response pattern 
(Figure 3.14b). Responses to the chemotherapy (doxorubicin) and the EGFR pathway 
inhibitor (erlotinib) were high for the growth phenotype. In contrast, cancer cell lines 
classified as the survival phenotype responded well to drugs targeting components of the 
PI3K pathway, such as Sigma-Aldrich AKT1/2 inhibitor, neratinib, and bafilomycin. 
In addition to the bifurcation of GFRN and drug response, breast tumor cells of 
the growth phenotype showed a higher response to the specific MCL-1 inhibitor UMI-77 
(Figure 3.14b). This is consistent with the findings that samples within the growth 
phenotype have higher MCL-1 expression than the survival phenotype. Response to 
obatoclax could not be clearly distinguished based on these phenotypes, likely due to its 
nonspecific binding to pro-survival proteins, including BCL-2, BCL-XL, and MCL-1 
(Goard, Schimmer, 2013). Overall, the GFRN phenotype-based drug response predictions 
were validated in this independent drug response assay. Additionally, drug sensitivity of 
emerging therapies such as UMI-77, neratinib, and bafilomycin showed differences 
between the two phenotypes, further highlighting the close relationship between GFRN 
signaling activity and response to therapies directed at pathways in this network. 
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When GFRN phenotype subgroups were considered, several drugs in the ICBP 
drug response assay showed significantly different drug response profiles in the 
subgroups found in each GFRN phenotypic arm. For example, the PI3K and mTOR 
inhibitor GSK1059615 and HER2/EGFR-targeting drug lapatinib were more effective in 
cell lines within the survival phenotype showing higher HER2 activity (p = 0.009 and 
p < 0.000001, respectively; Figure 3.15a, b). Additionally, ICBP cell lines expressing the 
growth phenotype responded better to EGFR-targeting drugs AG1478 and gefitinib in the 
EGFR/BAD low cluster compared to the EGFR/BAD high cluster (p = 0.001 and 
p = 0.001, respectively; Figure 3.15c, d). 
 
Figure 3.15. Differential drug response identified in GFRN phenotype heterogeneity. Boxplots of –log(EC50) drug 
response data from four drugs in the drug assay that show a differential drug response within growth factor phenotypes. 
a. GSK1059615, a PI3K and mTOR inhibitor, caused an increase in response in samples within the survival phenotype 
classified as having high HER2 activity. b. Lapatinib, a HER2 inhibitor, stimulated a stronger response in samples 
within the survival phenotype with high HER2 activity. c. AG1478 and d. gefitinib, EGFR inhibitors, caused an 
increased response in samples within the growth phenotype classified as having low BAD activity. 
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To determine if this bifurcation pattern was independent of clinical and intrinsic 
subtyping approaches, the correlations between pathway activation and drug response for 
ER+ and ER- and HER+ and HER- ICBP cell lines were clustered separately. Again, cell 
lines with high AKT/IGF1R/HER activity, i.e., the survival phenotype, were more 
sensitive to HER2/AKT/PI3K-targeted drugs even within ER- and HER- cell lines 
(Figure 3.16) In ER+ and HER+ cell lines, many PI3K/AKT/HER2-targeting drugs are 
more effective in the survival phenotype, as expected. However, there was additional 
drug response heterogeneity within ER+ samples that is associated with variations in 
BAD and HER2 pathway activity. These subgroups are thus helpful to further classify 
samples for better drug response prediction. To assess drug response across ER, PR, and 
HER2 status and intrinsic subtypes, it was found that out of 90 drugs studied in ICBP 
only 13 (14.4%), 12 (13.3%), and 19 (21.1%) showed significant differences in drug 
response based on ER, PR, and HER2 status, respectively, but growth/survival 
phenotypes were significant for 27 (49%). As further evidence, while HER2 positive 
status is a biomarker for effective HER2-targeted therapy, drug sensitivity does not solely 
depend on HER2 status. For example, while HER2 status performs much better in 
differentiating lapatinib’s response than ER and PR status (p < 0.0001), some HER2- cell 
lines, such as HCC70 and 184A1, may respond to lapatinib. The subgroup analysis 
showed the survival/HER2 high subgroup to be more sensitive to lapatinib than any other 
subgroup (Figure 3.15b). In contrast, intrinsic subgroup analysis showed, in general, that 
the luminal subtype was more sensitive, but significant variability in lapatinib sensitivity 
exists within the luminal subtype. Other detailed examples describing comparisons 
between the GFRN phenotypes and other methods are included in Figure 3.15. In 
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conclusion, the GFRN phenotypes provide additional information to current approaches; 
GFRN phenotypes and subgroups could be used to further stratify samples and may help 
select more appropriate candidates for effective drug response. 
 
Figure 3.16. Correlations between pathway activation estimates and drug response values between ER+ and ER- 
and between HER+ and HER2- samples in breast cancer cell lines. Colors correspond to scaled Spearman 
correlations between specific pathway activation estimates generated with ASSIGN and drug sensitivity (-logGI50) 
across a. 18 ER+ breast cancer cell lines, b. 32 ER- breast cancer cell lines from the ICBP panel, c. 18 HER2+ breast 
cancer cell lines, and d. 32 HER2- breast cancer cell lines from the ICBP panel. Red represents positive correlation and 
blue represents negative correlation. Pathways cluster across the x-axis as (coral color) survival phenotype and (green) 
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growth phenotype. Drug classes are represented along the y-axis as pink (HER2/AKT/PI3K/mTOR targeted-therapies), 
yellow (chemotherapies/BCL-2 targeting therapies), and blue (EGFR/MEK targeted-therapies). 
Discussion 
 
Figure 3.17. Summary of the survival and growth phenotypes in breast cancer. The survival phenotype is 
characterized by high HER2, IGF1R, and AKT pathway activation, high expression of pro-apoptotic BIM, low 
expression of anti-apoptotic MCL-1, and response to HER2, AKT, PI3K, and mTOR inhibitors. The growth phenotype 
is characterized by high EGFR, KRAS, and RAF1 activation, high expression of MCL-1, low expression of BIM, and 
response to EGFR/MEK-targeted therapies and chemotherapies. 
 Targeted therapies directed against the key members of the growth factor receptor 
network (GFRN), such as EGFR, PI3K, AKT, and mTOR inhibitors, are currently in 
preclinical development, clinical trials, or approved for use in breast cancer (Paplomata, 
O'Regan, 2014). However, predicting patients’ responses to therapies is challenging due 
to difficulties in measuring complex signaling events in tumors. Here, this issue was 
addressed by investigating global GFRN activity in breast cancer using these novel 
signatures. Two discrete patterns of GFRN pathway activity, or phenotypes, were found 
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(Figure 3.17). The survival phenotype was characterized by the activation of the HER2, 
AKT, and IGF1R pathways, and the growth phenotype by the activation of the EGFR, 
KRAS, RAF1, and BAD pathways. Additional subgroups were also found within the 
survival and growth phenotypes, including HER2 high and low activity groups within the 
survival phenotype and BAD high and low activity groups within the growth phenotype. 
Although these discrete phenotypes were named the survival and growth phenotypes for 
simplicity, GFRN pathways comprising both groups can contribute to growth and 
survival. To the best of our knowledge, this is the first study to characterize GFRN 
activity using signature-based representations of activity across multiple pathways. 
 These discrete subgroups displayed differences in response to targeted therapies 
and chemotherapies in breast cancer cell lines. For example, conventional 
chemotherapies such as docetaxel, paclitaxel, and doxorubicin were more effective for 
the growth phenotype than the survival phenotype. Sensitivity to PI3K, HER2, AKT, and 
mTOR inhibitors and resistance to conventional chemotherapies were also found in the 
survival phenotype. Among the subgroups, the survival phenotype/high HER2 subgroup 
was hypersensitive to lapatinib, a HER2 and EGFR dual inhibitor. Similarly, the survival 
phenotype/high HER2 subgroup was more sensitive to GSK1059615, a PI3K/mTOR 
inhibitor than the survival phenotype/low HER2 subgroup. Cell lines of the growth 
phenotype responded better to EGFR and MEK inhibitors and to conventional 
chemotherapies. The growth phenotype/low BAD subtype was more sensitive to both 
AG1478 and gefitinib (EGFR inhibitors) than the growth phenotype/high BAD subtype. 
Overall, the GFRN pathway-based phenotyping contributed to information related to 
drug response. 
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 Analysis of these novel phenotypes in breast cancer cell lines and tumors also 
revealed interesting differences in intrinsic apoptosis. For example, breast cancer cell 
lines and tumors of the growth phenotype had higher levels of the anti-apoptotic protein 
MCL-1 and lower levels of the critical pro-apoptotic protein BIM. These results are 
consistent with the notion that the MAPK pathway can activate MCL-1 expression and 
that activation of ERK1/2 and the MAPK pathway can repress BIM (Townsend et al., 
1998, Weston et al., 2003, Ley et al., 2003, Deng et al., 2007). An independent drug 
assay also showed that the growth phenotypic cell lines responded better to a MCL-1 
inhibitor (UMI-77). These results suggest that the patients with growth phenotypic 
expression may benefit from treatments that increase BIM, i.e., MCL-1 inhibitors, in 
combination with chemotherapies, EGFR inhibitors, or other inhibitors of the MAPK 
pathway (Akiyama, Dass & Choong, 2009, Faber et al., 2011). Therefore, targeting 
GFRN members may be an effective therapeutic strategy for inhibiting GFRN pathways 
and increasing apoptosis (Letai, 2008). These results highlight that mapping phenotypes, 
such as growth networks in breast tumors, can be exploited to guide the use of targeted 
therapies. This study was limited to how GFRN activity related to drug response and 
cellular intrinsic apoptosis, but it is understood that this is not the sole mechanism by 
which cancer cells die, and other cell death mechanisms, such as necrosis, autophagy, and 
mitotic catastrophe, should also be considered. In addition, as the use of cell lines is 
limited, a larger-scale analysis of apoptotic pathways dysregulation in patient tumor cells 
of all subtypes will be informative in further detailing how these pathways signal in 
cancer. These phenotypes may correlate with other subtyping properties, and may also be 
confounded by properties of intrinsic subtyping. 
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 Importantly, these newly discovered breast cancer survival and growth 
phenotypes are biologically relevant and offer a direct method for probing and targeting 
the GFRN in breast tumors. In addition, these phenotypes complement widely used 
clinical and intrinsic subtypes, and stratification of cancers by these phenotypes leads to 
enhanced drug response predictions compared to classifying cancers by clinical subtyping 
approaches. This is most likely because oncogenic pathway activation was measured 
more comprehensively than relying on single protein measurements. In addition, this 
approach considers crosstalk between members of the GFRN and correlates with 
biological processes such as cell survival. This pathway-based approach for identifying 
phenotypes allows for exploration of additional heterogeneity occurring within the 
identified phenotypes, which can further improve the ability to stratify breast cancers by 
pathway activity, which then can be used to predict drug response. Although this method 
has added to current approaches for predicting drug response in breast cancer, most 
experiments were performed in breast cancer cell lines with particular classes of drugs; 
additional drug testing should be performed in breast cancer patient cells in order to 
confirm these phenotypes. 
 In summary, a novel genomic pathway-based approach of characterizing the 
interactive GFRN activation in breast cancer was used to discover two discrete GFRN 
phenotypes with significant differences in cell survival mechanisms and drug response in 
breast cancer. These phenotypes captured the distinct bifurcation pattern seen in gene 
expression, the GFRN pathway activity, mitochondrial apoptotic network protein 
expression, and drug response (Figure 3.17). While ER, PR, HER2 status and, more 
recently, intrinsic subtype are used to guide breast cancer treatment, these subtyping or 
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classifying approaches may not describe signaling pathway dysregulation in tumor cells. 
Pathway activity data provide additional information about tumor cells that can be 
leveraged to predict drug response. Characterizing individual tumors into these 
phenotypes can help determine which patients will benefit from a treatment and select the 
appropriate subpopulations for clinical trials. Importantly, these seven pathways did not 
capture all of the heterogeneity of the samples and inclusion of other pathways may have 
additional benefits. Although feasible, additional investigation is needed before these 
phenotypes can be used in clinical trials for patient selection, including the testing of 
these phenotypes in patient primary tumor cells. 
Conclusion 
 A discriminating bifurcation pattern of key GFRN pathways was identified in 
breast tumors that expands beyond histological and clinical subtypes. These phenotypes 
correlated with unique apoptotic and drug response mechanisms. The ability to measure 
signaling events more accurately in patient tumors advances understanding of the 
biological basis of cancer. These results may lead to more effective and individualized 
treatment selection in patients with breast cancer. 
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Chapter 4. Pathway signature profiling of tuberculosis RNA-Seq data 
Introduction 
 Tuberculosis (TB) is an infectious disease that is among the top ten causes of 
death worldwide (World Health Organization, 2016). Active TB disease is treated with a 
6 to 9 month course of antibiotics (Dorman, Chaisson, 2007). In India, the treatment 
success rate for new and relapse patients in 2016 was 69% (World Health Organization, 
2016). Predicting and understanding why some patients eventually fail TB treatment 
could help personalize TB treatment and improve treatment outcomes. 
Previously, gene expression biomarkers have been developed to detect patients 
with active TB disease, patients that are at risk of TB treatment failure, or patients that 
have a latent TB infection that is likely to progress to active TB disease (Zak et al., 2016, 
Bloom et al., 2013, Suliman et al., 2018, Thompson et al., 2017, Leong et al., 2018). 
Gene lists can be analyzed using tools such as Gene Set Variation Analysis (GSVA), 
Single Sample Gene Set Enrichment analysis (ssGSEA), or Adaptive Signature Selection 
and Integration (ASSIGN) to create a single score that represents the activity of the set of 
genes, which can then be used as a predictor (Hänzelmann, Castelo & Guinney, 2013, 
Shen et al., 2015, Barbie et al., 2009). These gene signature scores can also be used to 
stratify samples into groups that show similar TB signature activity. These groups can be 
used to understand the heterogeneous response to TB and help identify the pathways and 
underlying biology of TB disease progression. 
To assist researchers in applying a large set of TB signatures to available datasets, 
a set of 30 previously published signatures of TB disease was collected. This set of 
signatures has been included in the TB Signature Profiler, a novel R package that allows 
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users to quickly and easily perform pathway enrichment analysis using a set of signatures 
and multiple methods in an easy to use analysis framework for profiling and visualizing 
these pathways using simple, user friendly R functions. 
The TB Signature Profiler was applied to a novel TB dataset to understand gene 
expression differences between TB patients who successfully cleared active TB disease 
and those who failed treatment. Samples from TB patients were collected and monitored 
over time. After the course of treatment, baseline samples from patients that successfully 
treated TB and those that failed treatment were sequenced. Additionally, samples from 
treatment failure patients were also sequenced at a two-month mid-treatment timepoint. 
Decreased predicted TB pathway activity was observed in the month two treatment 
failure samples when compared to baseline samples. Additionally, treatment failure 
samples from patients that reported missed treatment doses showed higher TB signature 
activity when compared to patients that reported adherence to the prescribed treatment. 
No previously published signature was able to accurately predict treatment failure at 
baseline, and no significant differentially expressed genes that could stratify treatment 
failure samples were found. These results serve as an example of the kind of analysis that 
can be performed using the TB Signature Profiler. 
Methods 
Sample Processing and Sequencing 
Patients with active TB were monitored over the course of TB treatment. Samples 
were collected at baseline, and at two-month timepoints. After treatment, subjects were 
categorized as either control (successful TB treatment) or failure (TB treatment failure). 
RNA sequencing libraries were prepared for samples from 21 baseline control samples, 
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20 baseline failure samples, and 20 month two failure samples. Multiplex Illumina 
sequencing was performed on the samples using 100 base pair paired end reads to yield 
an average of 37 million read pairs per sample. 
RNA-Seq Data Analysis 
Quality control was performed on the raw sequencing FASTQ read files using 
FastQC and MultiQC (Babraham Bioinformatics, 2011, Ewels et al., 2016). Reads were 
aligned to the human reference genome (hg19) using Rsubread, version 1.30.5 (Liao, 
Smyth & Shi, 2013). Samples had an average alignment percentage of 82% (range 62-
89%). Read counts for each gene were calculated using the featureCounts() function 
from the Rsubread package and gene annotations from the UCSC refGene database 
(Karolchik et al., 2004). An average of 70% of the reads were successfully assigned to a 
gene (range 55-75%). The count matrix was normalized and scaled by calculating 
fragments per kilobase of transcript per million mapped reads (FPKM) and transcripts per 
million (TPM) values. Normalized values were log transformed for downstream analysis. 
The count matrix, normalized matrices, and annotation information were loaded into R 
and stored in a SummarizedExperiment object for downstream analysis (Huber et al., 
2015). To check for obvious outlier samples, random subsets of genes were visualized 
using a heatmap. One baseline failure sample showed consistently anomalous expression 
that could not be corrected and was excluded as an outlier. 
For additional analysis comparing the failure data to LTBI samples, the failure 
dataset was combined with the India TB vs. LTBI RNA-Seq dataset available from GEO 
at GSE101705 (Leong et al., 2018). Log normalized TPM values were combined and 
  
89 
batch correction using ComBat was performed to remove the sequencing batch effect 
between the two datasets (Johnson, Li & Rabinovic, 2007). 
Collection of Published TB Signatures 
 
Figure 4.1. Overlap of genes in the TB signature cohort listed in 5 or more signatures. Of the 1,392 unique genes 
in the 30 signatures, 37 are listed in 5 or more signatures. The majority of these signature genes are contained in the 
large Esmail 893 gene, Berry 393 gene, and Blankley 380 gene signatures. 
A set of previously published gene signatures of TB disease and TB disease 
progression were collected. Signatures designed to distinguish TB disease vs LTBI or 
healthy samples include the 16 gene “ACS_COR” signature (Zak et al., 2016), the 393 
gene Berry signature (Berry et al., 2010), the 380 gene Blankley signature (Blankley et 
al., 2016), the 893 gene Esmail signature (Esmail et al., 2018), the 3 gene Jacobsen 
signature (Jacobsen et al., 2007), the 27 gene Kaforou signature (Kaforou et al., 2013), 
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the 4 gene Lee signature (Lee et al., 2016), the 4 gene Suliman “RISK4” signature 
(Suliman et al., 2018), the 51 gene Walter signature (Walter et al., 2016), and the 42 gene 
Anderson signature (Anderson et al., 2014). Signatures that distinguish TB disease vs 
LTBI or other diseases include the 51 gene Anderson signature (Anderson et al., 2014), 
the 86 gene Berry signature (Berry et al., 2010), the 140 gene Bloom signature (Bloom et 
al., 2013), the 53 gene Kaforou signature (Kaforou et al., 2013), the 44 gene Kaforou 
signature (Kaforou et al., 2013), the 100 gene Maertzdorf signature (Maertzdorf et al., 
2012), the 4 gene Maertzdorf signature (Maertzdorf et al., 2016), the 4 gene Roe 
signature (Roe et al. 2016), the 20 gene Singhania signature (Singhania et al., 2018), and 
the 3 gene Sweeney “DIAG3” signature (Sweeney et al., 2016). The Blankley 5 gene 
signature distinguishes active TB disease from healthy, LTBI, or post treatment samples 
(Blankley et al., 2016). The 9 gene “DISEASE” signature, the 13 gene “FAILURE” 
signature, and the 5 gene “RESPONSE5” signature predict treatment failure and response 
to treatment (Thompson et al., 2017). The 203 gene and 82 gene Esmail signatures were 
designed to distinguish subclinical TB disease and LTBI (Esmail et al., 2018). The 10 
gene Sambarey signature identifies TB disease from LTBI samples in the context of HIV 
infection (Sambarey et al., 2017). The 2 gene Sloot signature predicts TB disease 
progression in the context of HIV (Sloot et al., 2015). Finally, the 47 gene and 119 gene 
Walter signatures identify TB disease in the context of Pneumonia (Walter et al., 2016). 
All signature gene lists were compared to the gene annotations in the UCSC hg19 human 
reference genome. Signature genes that did not have a corresponding gene included in the 
hg19 gene annotation or genes that mapped to duplicate gene annotations in hg19 were 
removed. The 30 signatures consist of 1,392 unique TB associated genes. The majority of 
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the genes (878, 63%) are listed in a single signature and 97.3% (1,355 genes) are listed in 
four or fewer signatures, with 37 (2.7%) genes listed in five or more signatures (Figure 
4.1). Genes that occur frequently in the signatures include FCGR1A, FCGR1B, GBP5, 
and GBP4 (in 12, 10, 10, and 10 of the signatures, respectively). 
Differential Expression Analysis 
Limma was used to identify differentially expressed genes in the baseline samples 
(Ritchie et al., 2015). Log transformed TPM values and the default limma parameters 
were used. An FDR corrected p-value of 0.05 was used to determine if a gene was 
differentially expressed between baseline control and baseline failure samples. Available 
covariates were added to the limma differential expression model to see if correcting for 
other sources of variation would produce differentially expressed genes. Smoking status, 
diabetes status, cough duration before treatment, random blood sugar, number of 
alcoholic drinks per day, age, sex, time to positive diagnosis, and smear result were each 
added to a limma model along with control vs. failure (limma model ~control_vs_failure 
+ covariate). DESeq2, another method for differential expression analysis, was performed 
to try to identify differentially expressed genes (Love, Huber & Anders, 2014). Raw 
count values and the default DESeq2 parameters were used. 
Gene Set Analysis 
Several methods were used to perform gene set enrichment analysis. Single 
sample GSEA (ssGSEA) is an extension to the GSEA algorithm that provides a gene set 
enrichment score for each sample in a dataset given a gene list (Barbie et al., 2009). This 
is accomplished by ranking genes by absolute expression and calculating an enrichment 
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score for the genes in the signature based on this ranking. (Barbie et al., 2009). Gene Set 
Variation Analysis (GSVA) calculates a similar statistic, but by first calculating an 
expression-level statistic using kernel estimation (Hänzelmann, Castelo & Guinney, 
2013). Adaptive Signature Selection and Integration (ASSIGN) calculates signature 
activity scores using a Bayesian estimation framework to adapt signature genes to the 
specific context of the tested samples (Shen et al., 2015). Methods for performing 
ssGSEA and GSVA are provided in the GSVA package available on Bioconductor 
(Huber et al., 2015). ASSIGN is available as a standalone package on Bioconductor 
(Shen et al., 2015). Gene Set Enrichment Analysis (GSEA) was used to create enrichment 
score plots of signatures in a ranked list of genes based on a given phenotype 
(Subramanian et al., 2005). 
Visualization 
The ComplexHeatmap R package was used to create an annotated heatmap of 
pathway signature activities (Gu, Eils & Schlesner, 2016). Each row of the heatmap 
represents a TB signature, and each column represents a sample. Pathway activity scores 
were scaled to highlight the differences in pathway activity across samples and 
hierarchical clustering was used to identify samples that showed similar patterns of 
expression. Annotation information was added to the top of the heatmap as a color bar. 
Boxplots of signature activity were created using the ggplot2 R package 
(Wickham, 2010). Pathway activity scores for each signature were grouped based on 
annotation information. 
The ComplexHeatmap R package was used to create annotated heatmaps of 
individual signature activity (Gu, Eils & Schlesner, 2016). Each row of the heatmap 
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represents a gene in the TB signature, and each column represents a sample. Gene 
expression was scaled to highlight expression differences between samples. Annotation 
information was added to the top of the heatmap. Below the annotation information, 
pathway activity scores were added. The plotROC package was used to calculate AUC 
values, confidence intervals, and create ROC curves (Sachs, 2017). 
Software Availability 
Methods for performing gene set analysis using ssGSEA, GSVA, and ASSIGN, 
and visualizing the results using boxplots and heatmaps of pathway activity predictions 
were packaged into the TB Signature Profiler R package. The software utilizes the 
SummarizedExperiment framework to store raw expression data, annotations, and results 
within a single object. Raw expression data is stored as a set of multiple matrices called 
assays that must contain identical dimensions. Along with the assay data the user can 
provide sample annotation and gene annotation data that can be stored in the colData and 
rowData slots of the SummarizedExperiment object, respectively (Huber et al., 2015). 
Users run the gene set analysis using the runTBsigProfiler() function providing an 
input SummarizedExperiment object, the assay to use for profiling, and the algorithms to 
use for gene set analysis. The results of this analysis are per sample gene set enrichment 
scores that are stored in the colData slot of the SummarizedExperiment object that is 
returned by the runTBsigProfiler() function. The resulting gene set enrichment results 
can be visualized as described above using the signatureHeatmap(), 
signatureBoxplot(), and signatureGeneHeatmap() functions. The software is 
available on GitHub https://github.com/compbiomed/TBSignatureProfiler. 
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Results 
Previously published TB signatures show decreased TB signature activity at month two in 
TB failure samples 
 
Figure 4.2. Scaled GSVA pathway activity scores for baseline failure, baseline control, and month two failure 
samples. GSVA pathway activity scores are elevated in baseline control and failure samples and appear to decrease in 
the month two samples. Month two samples that have elevated TB signature activity tend to be from patients that 
reported missing doses during treatment. 
Using the TB Signature Profiler, GSVA scores were produced for each sample 
(Figure 4.2). Since baseline samples come from patients with active TB disease, TB 
pathway activity scores are elevated in baseline samples. At month two, pathway activity 
scores in 12 of the 30 tested pathways show significantly decreased activity levels when 
compared to all baseline samples (FDR corrected p-value < 0.05 in Blankley_5, 
Bloom_140, Roe_4, Sambarey_10, DISEASE_9, Blankley_380, 
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Kaforou_TB_vs_LTBI_27, ACS_COR_16, Anderson_TB_vs_other_LTBI_51, 
Berry_393, Jacobsen_3, and Suliman_RISK4). These decreased pathway activity scores 
could indicate an initial response to TB treatment, despite the fact that these patients 
eventually progress to treatment failure. 
 
Figure 4.3. Pathway activity scores from month two failure samples. Boxplots are split into adherent and non-
adherent groups based on the total number of missed doses reported on the DOTS card. Significant pathway activity 
differences are observed in 6 of the 30 tested pathways (FDR corrected p-value < 0.05), indicating that patients that 
adhere to the treatment protocol are showing decreased TB activity when compared to those that are non-adherent. 
In some month two samples, pathway activity levels have not decreased, causing 
these samples to cluster with the baseline samples with higher pathway activity levels. 
These elevated levels of TB pathway signaling tend to occur in patients that have missed 
doses in their treatment (as reported on the DOTS card), indicating that this difference 
could be due to patients not adhering to the treatment protocol. Significant differences 
between adherent and non-adherent patients were observed in 6 of the 30 pathways 
(Figure 4.3). If the non-adherent samples are removed, 16 of the 30 pathways identify a 
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significant difference between baseline and month 2 failure samples (FDR corrected p-
value < 0.05 in ACS_COR_16, Anderson_TB_vs_other_LTBI_51, Berry_393, 
Blankley_380, Blankley_5, Bloom_140, DISEASE_9, Jacobsen_3, 
Kaforou_TB_vs_LTBI_27, Kaforou_TB_vs_LTBI_other_53, Kaforou_TB_vs_other_44, 
Roe_4, Sambarey_10, Suliman_RISK4, Sweeney_DIAG3, and 
Walter_TB_vs_LTBI_51). 
 
Figure 4.4. Boxplot of ACS_COR signature scores in combined India failure and Leong et al. India datasets. 
LTBI samples show decreased pathway activity estimates for ACS_COR when compared to baseline TB and month 2 
failure non-adherent samples, but show similar pathway activity scores when compared to the month 2 adherent 
samples. 
To compare the adherent and non-adherent samples to additional Indian TB 
samples, the failure data was combined with a previously published dataset (Leong et al., 
2018). The Leong et al. dataset contains 28 samples with active TB disease and 16 LTBI 
samples, which have previously been shown to have differences in pathway activity 
ACS_COR_16
Baseline
LTBI
Baseline
TB
M2 Failure
Adherent
M2 Failure
Non−adherent
−0.5
0.0
0.5
1.0
Group
Sc
or
e
Group
Baseline
LTBI
Baseline
TB
M2 Failure
Adherent
M2 Failure
Non−adherent
Signatures
  
97 
signatures. After combining this data with the India failure dataset and adjusting for batch 
effects using ComBat, GSVA was used to profile the samples using the ACS_COR 16 
gene signature. Baseline samples with active TB disease showed elevated ACS_COR 
signature scores when compared to the LTBI samples and the non-adherent month 2 
samples (Figure 4.4). Adherent month two samples show decreased ACS_COR signature 
scores similar to those of LTBI samples. 
Existing signatures of TB fail to distinguish TB treatment failures at baseline 
Signature AUC (95% CI) 
ACS_COR (16 gene) 0.543 (0.357-0.721) 
Anderson TB vs. LTBI (42 gene) 0.610 (0.431-0.776) 
Anderson TB vs. other/LTBI (51 gene) 0.507 (0.329-0.688) 
Berry (393 gene) 0.583 (0.402-0.760) 
Berry (86 gene) 0.576 (0.395-0.752) 
Blankley (380 gene) 0.679 (0.505-0.833) 
Blankley (5 gene) 0.543 (0.276-0.643) 
Bloom (140 gene) 0.648 (0.469-0.807) 
DISEASE (9 gene) 0.562 (0.381-0.736) 
Esmail subclinical (203 gene) 0.576 (0.393-0.752) 
Esmail subclinical (82 gene) 0.510 (0.305-0.679) 
Esmail TB vs LTBI (893 gene) 0.579 (0.395-0.748) 
FAILURE (13 gene) 0.548 (0.362-0.721) 
Jacobsen (3 gene) 0.643 (0.459-0.812) 
Kaforou TB vs LTBI (27 gene) 0.576 (0.393-0.750) 
Kaforou TB vs LTBI/other (53 gene) 0.550 (0.364-0.736) 
Kaforou TB vs other (44 gene) 0.614 (0.443-0.783) 
Lee (4 gene) 0.662 (0.476-0.833) 
Maertzdorf (100 gene) 0.543 (0.360-0.721) 
Maertzdorf (4 gene) 0.600 (0.417-0.771) 
RESPONSE5 (5 gene) 0.538 (0.355-0.717) 
Roe (4 gene) 0.521 (0.290-0.664) 
Sambarey (10 gene) 0.567 (0.381-0.741) 
Singhania (20 gene) 0.657 (0.486-0.817) 
Sloot (2 gene) 0.571 (0.388-0.743) 
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Suliman RISK4 (4 gene) 0.593 (0.405-0.769) 
Sweeney DIAG3 (3 gene) 0.552 (0.371-0.731) 
Walter TB vs LTBI (51 gene) 0.505 (0.317-0.676) 
Walter TB vs Pneumonia (47 gene) 0.514 (0.333-0.700) 
Walter TB vs Pneumonia/LTBI (119 gene) 0.555 (0.362-0.738) 
Table 4.1. AUC Values and 95% confidence intervals for pathway activity predictions using GSVA scores to 
predict failure samples. All existing signatures show poor predictive power for pathway failure. All 95% confidence 
intervals contain 0.5 with the exception of the Blankley 380 gene signature. 
 
Figure 4.5. ROC Curves of ACS_COR and FAILURE signatures in baseline samples. Previously published 
signatures of TB activity and treatment failure fail to distinguish TB samples vs controls at baseline in the India data. 
Left: ACS_COR AUC=0.543 (95% CI: 0.362-0.724). Right: FAILURE_13 AUC=0.548 (95% CI: 0.364-0.721). 
None of the GSVA scores for the 30 TB signatures show a significant difference 
in pathway activity levels at baseline (FDR corrected p-value > 0.6 for all pathways). 
When visualized using a heatmap, pathway activity levels at baseline do not separate by 
treatment failure vs control (Figure 4.2). The AUC values for all thirty signatures show 
poor predictive ability to distinguish the samples at baseline (Table 4.1). Previously, a 
thirteen gene signature of treatment failure was produced and shown, along with the 
ACS_COR signature, to accurately predict treatment failure in TB samples (Thompson et 
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al., 2017). At baseline, these genes fail to separate baseline failure and baseline control 
samples in this cohort (ACS_COR: AUC=0.543 (95% CI 0.357-0.721) Figure 4.5 left, 
FAILURE: AUC=0.548 (95% CI 0.362-0.721) Figure 4.5 right, Figure 4.6). To test if 
this failure signature was enriched in our treatment failure samples at baseline, a GSEA 
analysis was performed. The genes show no enrichment when compared to all genes 
ordered by their difference between control and failure samples (FDR corrected p-value > 
0.99 Figure 4.7). 
 
Figure 4.6. Heatmap of row scaled log(TPM) gene expression data for the FAILURE 13-gene signature in 
baseline India samples. Gene expression differences in the 13 gene signature do not separate failure and control 
samples. The top color bar indicates the subject type and the second color bar indicates the predicted pathway activity 
scores from GSVA from the FAILURE signature. The separation in this heatmap is not associated with sequencing 
batch or any other annotation information available for these samples. 
To confirm the pathway activity methods employed by the TB Signature Profiler 
can be used to effectively predict pathway activity differences using this signature, a 
reanalysis of the dataset in Thopmson et al. was performed. The Thompson et al. cohort 
contains samples from patients with active TB at several time points (baseline, day seven, 
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week 4, and week 24) that are categorized into groups of “Not Cured”, “Possibly Cured”, 
“Probably Cured”, and “Definitely Cured”. Baseline “Not Cured” samples (n=7) show a 
significantly lower failure signature score when compared to baseline “Definitely Cured” 
samples (n=71). To determine if the failure signature is an effective predictor of treatment 
failure at baseline in the Thompson et al. cohort, AUC values were calculated (Figure 4.8 
right, AUC=0.938, 95% confidence interval 0.865-0.988). 
 
Figure 4.7. GSEA enrichment of 13-gene failure signature on baseline samples using gene set enrichment 
analysis. Enrichment score indicates enrichment of the gene list of interest in all genes sorted by their difference 
between control and failure samples. FAILURE genes are not significantly enriched in up- or down- regulated genes 
(FDR corrected p-value > 0.99). 
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Figure 4.8. GSVA pathway activity scores for FAILURE signature in baseline Thompson et al. samples. a. 
Boxplot of GSVA pathway activity scores at baseline for not cured and definite cure samples. b. ROC curve for GSVA 
scores to predict treatment failure at baseline in the Thompson et al. cohort AUC=0.938 (95% CI: 0.865-0.988). 
To test if the FAILURE signature is overfit to the Thompson dataset, “Not Cured” 
and “Definite Cure” labels were randomly shuffled across the 78 baseline samples used 
to create the signature. Limma was used to identify 13 genes that best separate the two 
groups of samples using the shuffled labels. The GSVA score was then calculated for the 
shuffled labels and the AUC was calculated. This process was repeated 10,000 times. The 
median AUC of the iterations was 0.843 with 23.1% of the AUC values being 0.938 or 
higher, indicating this data produces a signature that is overfit. 
No significantly differentially expressed genes separated baseline controls and TB 
treatment failures 
Since none of the existing TB signatures effectively predicted TB treatment 
failure at baseline in the India cohort, differential expression analysis was performed to 
identify genes that showed significant differences in expression at baseline between 
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control and failure samples. Using limma, no genes were found to be significantly 
differentially expressed at a corrected p-value < 0.05. To ensure no additional sources of 
variability were affecting the analysis, covariates from available sample annotations were 
added to the limma model including smoking status, diabetes status, cough duration 
before treatment, random blood sugar, number of alcoholic drinks per day, age, sex, time 
to positive diagnosis, and smear result. Again, no genes reached a significance threshold 
p < 0.05 with any of the covariates added to the model. No differentially expressed genes 
at an FDR corrected p-value < 0.05 were identified. 
 
Figure 4.9. Differentially expressed genes at baseline as identified by DESeq2. Differential expression analysis 
using DESeq2 was performed on the baseline samples to identify genes that differentiate failure and control samples. 
Fourteen genes were identified using an FDR corrected p-value < 0.05 and a minimum absolute fold change of 2. When 
clustered using hierarchical clustering, these genes do not separate the data. 
To validate this result, DESeq2, another method for differential expression 
analysis, was performed to try to identify differentially expressed genes. 1,699 
differentially expressed genes were identified (FDR corrected p-value < 0.05). Of these 
1,699 genes, only 14 genes were found to be differentially expressed with a fold change 
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greater than two in either direction. When visualized, these significant genes failed to 
separate the differentially expressed genes, indicating that these genes do not represent a 
consistent potential biomarker for disease failure in the India cohort (Figure 4.9). 
Discussion 
 We have created the TB Signature Profiler, an R package for calculating and 
visualizing pathway activity scores using currently available tools including GSVA, 
ssGSEA, and ASSIGN. Because our package leverages the SummarizedExperiment 
framework, users can easily store their raw gene expression data, annotation information, 
and pathway activity scores together in a single R object, which can then be visualized. 
The signatureHeatmap() function can be used to plot a heatmap of pathway activity 
scores along with annotations (Figure 4.2). The signatureBoxplot() function can be 
used to create a boxplot of pathway activity scores based on a sample annotation (Figure 
4.3, Figure 4.8, left). Finally, the signatureGeneHeatmap() function can create a 
heatmap of an individual signature gene displaying gene expression values, annotation 
information, and pathway activity scores in a single plot (Figure 4.6). This tool allows 
researchers to profile a large set of previously described TB signatures automatically. 
Additionally, users can modify this list to subset the list of pathways to a specific set of 
interest, or add additional signatures as they become available. By visualizing these 
pathway activity scores together, users may identify additional heterogeneity that would 
not be visible using a single pathway activity prediction. 
 Using the TB signature profiler on our cohort of TB failure samples, we have 
identified a significant difference between baseline and month two failure samples, where 
the majority of the month two samples show a decrease in TB pathway activity scores. 
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This could indicate a response to treatment at two months in these samples, despite the 
fact that they will eventually go on to fail TB treatment. For samples that showed an 
elevated level of TB signature activity, these samples tended to be ones that reported 
missed doses during their treatment, which could indicate the utility of TB pathway 
signatures to help detect study adherence in TB cohorts, which could serve as a reliable 
biological check to ensure patients take their medications and that they are showing a 
response to treatment. Further, treatment adherence can have a confounding effect on 
pathway activity measurements and controlling for it could increase the predictive ability 
of TB biomarkers. 
 Using an existing signature of TB failure on our baseline samples, we failed to 
distinguish control samples from samples that eventually fail TB treatment. The 
previously published signature did not show enrichment in genes that show a difference 
in expression in the cohort, and appeared to be overfit in the dataset that was used to 
create it. Further, no previously published signature could be used to effectively predict 
TB treatment failure at baseline. 
 Differential expression analysis failed to identify a set of genes that reliably 
separate baseline control and failure samples in our dataset, despite controlling for 
various other possible sources of variation within the data. Samples appeared to cluster at 
random and any difference that was identified was minimal and not useful as a biomarker 
for TB failure. Although none of the available sample annotation information or 
sequencing batch information for these samples showed a significant association with the 
clustering, it cannot be ruled out that some unknown source of variation is masking true 
signal. 
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 To our knowledge, this is the largest set of previously published TB signatures 
that has been collected, and by using the TB Signature Profiler researchers will be able to 
leverage this set to profile their own datasets with minimum effort. Standardizing 
methods of pathway activity measurements will make the results of this analysis more 
consistent across studies and allow more direct comparisons between cohorts, leading to 
easier meta-analysis and new insights and better predictive and mechanistic insights into 
tuberculosis. 
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Chapter 5. Conclusion 
 The work presented in this dissertation represents a set of software tools and data 
resources that can be used across RNA-Seq technologies and disease areas to analyze and 
visualize RNA-Seq data. Specifically, novice users can use the SCTK to go from raw 
count data from scRNA-Seq experiments and perform common analysis and visualization 
methods interactively without writing any R code. This is the first time that a complete 
scRNA-Seq analysis workflow has been implemented in an easy to use point-and-click 
environment. The SCTK software framework is extendable and under active 
development, which will increase its utility with additional quality control visualizations, 
analysis techniques, and novel methods as they are developed. In the context of breast 
cancer, the set of novel growth factor receptor signatures that were created identify 
additional heterogeneity beyond currently available breast cancer subtyping through 
immunohistochemistry and showed differences in response to drug therapies. By directly 
profiling the biologically relevant pathways that can be targeted in breast cancer, the 
specific drivers of individual tumors can be identified, which could help stratify patients 
to give them the drugs that will target the specific oncogenic pathways driving their 
tumor. Finally, a pathway activity approach is also useful in tuberculosis, where existing 
pathway signatures can help stratify patient samples based on their pathway activity. By 
building the TB Signature Profiler, users can rapidly profile samples, compare the 
pathway predictions across multiple TB signatures, or develop new signatures to further 
stratify their samples, which could lead to a deeper understanding of the underlying 
pathway activity in latent tuberculosis infection or during active disease and improved 
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monitoring during TB treatment to ensure drug protocol adherence and ensure that drug 
therapy is working. 
 By creating software frameworks and data resources for scientists, the approaches 
developed here can be extended and expanded to address the changing needs of the RNA-
Seq analysis environment. In the case of the SCTK, additional analysis modules for cell 
type prediction, improved data handling, and support for larger and more complex 
datasets and meta-datasets can be developed within the existing SCTK framework. 
Additional pathway signatures targeting novel therapeutic targets and cell growth 
pathways will be developed using the methodologies developed to create the GFRN 
signatures. Finally, additional pathway targets can be profiled using the TB Signature 
Profiler framework, extending its utility beyond the 30 collected signatures. 
 Taken together, these tools represent a novel and widely applicable set of user-
friendly software tools and resources. These tools serve as a model of how analysis 
techniques can be packaged and be made available to users without a deep understanding 
of the underlying methodologies, but still allow users to perform sophisticated analyses 
using their own and public data resources, helping leverage these techniques across 
disease areas and address unmet diagnostic need.
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APPENDIX A: Cell lines used in the independent drug assay and the Western 
blotting experiments. 
Cell Line 
Dose 
Response 
Assay 
Western 
Blots for 
apoptotic 
proteins 
ER 
Status 
PR 
Status 
HER2 
Status 
Intrinsic 
Subtype Source 
Growth 
Media 
AU565 Y Y Negative Negative Positive HER2-
Luminal 
ATCC A 
BT549 Y Y Negative Negative Negative Claudin-
low 
ATCC B 
HCC1143 Y Y Negative Negative Negative Basal ATCC B 
HCC1395 N Y Negative Negative Negative Claudin-
low 
ATCC B 
HCC1419 Y Y Negative Negative Positive HER2-
Luminal 
ATCC B 
HCC1569 Y N Negative Negative Positive HER2-
Basal 
ATCC B 
HCC1806 Y Y Negative Negative Negative Basal ATCC B 
HCC1937 Y Y Negative Negative Negative Basal ATCC B 
HCC1954 Y Y Negative Negative Positive HER2-
Basal 
ATCC B 
HCC2218 Y Y Negative Negative Positive HER2-
Luminal 
ATCC B 
HCC3153 N Y Negative Negative Negative Basal Adi Gazdar 
(University 
of Texas-
Southweste
rn Medical 
Center) 
B 
HCC38 Y Y Negative Negative Negative Claudin-
low 
ATCC B 
HCC70 Y Y Negative Negative Negative Basal ATCC B 
Hs578T Y Y Negative Negative Negative Claudin-
low 
ATCC B 
JIMT1 Y Y Negative Negative Positive HER2-
Basal 
ATCC A 
MDAMB
231 
N Y Negative Negative Negative Claudin-
low 
ATCC B 
SKBR3 Y N Negative Negative Positive HER2-
Luminal 
ATCC B 
ZR75B N Y Negative Negative Negative Luminal Mark 
Lippman 
(National 
Cancer 
Institute) 
B 
21PT N Y Positive Unavaila
ble 
Unavaila
ble 
HER2-
Basal 
Ruth Sager 
(Dana–
Farber 
Cancer 
Institute) 
C 
BT474 Y Y Positive Positive Positive HER2-
Luminal 
ATCC A 
BT483 Y Y Positive Positive Negative Luminal ATCC B 
CAMA1 Y Y Positive Negative Negative Luminal ATCC A 
HCC1428 Y Y Positive Positive Negative Luminal ATCC B 
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LY2 N Y Positive Negative Negative Luminal Mark 
Lippman 
(National 
Cancer 
Institute) 
A 
MCF7 Y Y Positive Positive Negative Basal ATCC A 
MDAMB
175 
N Y Positive Negative Negative Unavailable ATCC B 
MDAMB
361 
Y N Positive Negative Positive HER2-
Luminal 
ATCC A 
SUM52P
E 
N Y Positive Negative Positive Luminal Asterand 
Bioscience 
D 
T47D Y Y Positive Positive Negative Luminal ATCC B 
ZR751 Y Y Positive Negative Negative Luminal ATCC B 
ZR7530 Y Y Positive Negative Positive HER2-
Luminal 
ATCC B 
 
Growth Media A: DMEM (Gibco), 10% FBS (Sigma), 1% Anti/Anti (Life Technologies) 
Growth Media B: RPMI (Gibco), 10% FBS (Sigma), 1% Anti/Anti (Life Technologies) 
Growth Media C: DMEM/F12 (Gibco), 5% FBS (Sigma), 10 ug/mL Insulin, 100 ng/mL Cholera Toxin, 20 ng/mL 
EGF, 500 ng/mL Hydrocortisone 
Growth Media D: F12 (Gibco), 5% FBS (Sigma), 5 μg/ml insulin, and 1 μg/ml hydrocortisone 
  
110 
 
APPENDIX B: Gene list of optimized gene numbers determined for each GFRN 
signature. 
20 Gene AKT Signature 
AKT1, CD248, IGFBP3, SPRR2A, CA9, BEX1, IGFBP5, EPGN, PPP1R3C, GRHL3, 
TNFAIP2, AKAP12, CTGF, ICAM1, LIF, CXCL3, DKK1, ITGB3, CXCL2, CXCL5 
250 Gene BAD Signature 
BAD, KLF2, LCE1F, RFC3, C8orf84, BOLA3, DLEU1, MRPS12, PTGES, SLC16A9, 
PIK3R3, COTL1, LINC00239, NOP16, OPCML, MPV17L2, NEK6, AIMP2, POLR3G, 
SRM, SPINK6, C19orf48, CKS2, PRMT3, SLC25A15, PAICS, PMM2, CYCS, C14orf1, 
DCTPP1, C20orf27, CDC20, NETO2, GBP6, LSM2, TFAP4, RBBP8, ISCA1, 
PRADC1, MYL9, ORC6, PYCRL, PLA2G7, C11orf82, SLC25A10, PPIF, MRPS2, 
LOC100506895, FAM216A, LOC100506844, TMEM241, CYB5B, NME4, UFSP1, 
RHOB, TIPIN, LINC00162, CHCHD8, OSR1, EGFLAM, CDK4, FLJ39051, NME1, 
NEFL, MBLAC2, FLJ42351, CMC2, ZNF593, LIX1L, SORD, RWDD2B, NIP7, RRM2, 
ALDH1B1, C3orf26, ALDH1L2, POLR3K, SSR3, PRPS1, RASSF6, RAD51AP1, 
TOMM5, PDK1, RPP40, RRS1, FAM198B, C21orf63, LOC100128881, RRP9, 
CHCHD3, FAM86EP, MRPL12, C11orf83, ZDHHC14, TMED2, SFRP1, SELRC1, 
GPATCH4, CT62, CLEC2D, PDSS1, GAPDH, THEM4, MMACHC, MT1G, 
LOC401397, MKI67IP, NPM1, TUBA1C, SNORD16, LYAR, POLR3H, LYRM4, 
RUVBL1, NCL, TOMM20, VIM, TUBA1B, CCNB1, CDT1, COQ2, DCLRE1B, PPAT, 
C11orf24, PEG10, HSPA6, HSPA7, HSPA1A, IL8, DNAJA4, HSPA1B, CCL20, 
FOXQ1, GDF15, CXCL5, CRYAB, IL17C, TNFAIP2, CFB, KRT23, CXCL2, SAA2, 
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ATF3, DLC1, FOS, NFKBIZ, MYO5C, PRSS22, ERRFI1, CXCL3, DUSP2, ATHL1, 
AKAP12, FOSB, LIF, INHBA, GABRE, CDRT1, CXCL6, EGR3, DUSP1, HSP90AA1, 
ZFAND2A, HMOX1, BMF, RRAD, GSDMB, BIRC3, GRB7, HSPH1, SLC34A2, LTF, 
FERMT3, SGPP2, GAB2, BAG3, KRT80, HSPB8, DNAJB4, LCN2, DEDD2, CXCL1, 
TNFRSF11B, DUSP6, MUM1L1, TIAM2, KLHL24, OLFM4, BCORL1, DFNB31, 
IFRD1, DAPK1, STARD13, ETS1, NFKBID, TLR2, PRDM1, LOC146880, IER5, IER3, 
DNER, SAA1, PNLDC1, GPRC5A, STON1, ZC3H12A, GSDMC, GM2A, PDZD2, 
MAFF, GDF6, SBSN, SEMA6C, DNAJC6, PPP1R15A, DUSP5, LIMCH1, CLDN4, 
RB1CC1, MGAT4A, NYNRIN, DNAJB1, PLEKHA6, FNIP2, ABCA1, PLA2G4C, 
ULK1, IL7R, ENGASE, C17orf103, SLC24A6, CNNM3, AGAP11, GLCCI1, CCL2, 
IL17RB, ABCG1, DDIT3, CACHD1, ABTB2, SATB1, INSR, TMEM2, TNFSF14, 
GCNT2, ARHGAP19, ZNF217, BRD3, CYLD, IL34 
50 Gene EGFR Signature 
EGR1, IFI6, MT2A, MMP3, MT1X, EGR3, DUSP6, CCNA1, GJB2, IFI27, S100A9, 
MT1G, LINC00525, IL7R, IFITM1, IL6R, OGFRL1, MT1E, DLL1, SYT12, LTF, 
WDHD1, SOCS3, MCM5, ODZ2, KRT4, KRT81, SPINK6, SAMD11, KRT86, WISP2, 
KRT85, ATOH8, HSPB3, MMP7, ALPP, IFITM10, CD24, PGF, DIO2, ID2, CRYAB, 
HSPB8, IGSF23, CLDN7, DLX3, MAOA, WNT7B, BCO2, EGFR 
10 Gene HER2 Signature 
ERBB2, PNMA2, PDGFB, EEF1A2, MIR3944, HSPA6, HSPA7, IFIT1, DNAJA4, 
CCL2 
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100 Gene IGF1R Signature 
IGF1R, BHLHA15, DDIT3, CHAC1, ZSCAN12P1, RND1, CRELD2, PDIA4, 
C12orf39, HSPA5, ZNF165, ATF3, HERPUD1, STC2, PTX3, FICD, CDC6, SLC7A11, 
C17orf28, IRF1, SDF2L1, DNAJB9, ANXA6, KLHDC7B, DDR2, ERO1LB, HYOU1, 
AGR2, CNTD2, SEL1L, HSP90B3P, ADM2, ASNS, HSP90B1, DERL3, CCL2, 
DNAJC3, PSAT1, MSTO2P, SH3BGR, ALDH1L2, TMEM50B, NUCB2, ICAM1, 
GDF15, SOCS3, PCK2, KIAA0226L, WARS, FBXO16, DNAJA4, HSPA6, HSPA1A, 
HSPA7, ACTBL2, CRYAB, HSPA1B, OXTR, CXCL6, HSP90AA1, ATHL1, HMOX1, 
DKK1, LCE1C, CDSN, ALDH1A3, OLFM4, PDK4, CLDN4, HSPB8, HSPB2, 
RAD23A, GM2A, HSPH1, C4orf26, HSPA8, DNAJA1, BMP4, BAMBI, SLIT2, 
HSD17B11, FAM101B, FKBP4, BID, GDF6, BCAS4, CACYBP, TTYH2, RASA3, 
C10orf10, MAP2K3, FLNC, FAM25A, BAG3, CCNE1, PCGF3, SRRM3, ADCK3, 
PLSCR4, ANKRD1 
200 Gene KRAS (G12V) Signature 
MAL, KRAS, LCE3D, DHRS9, LCE3E, NPTX1, IL1RL1, PRSS22, PRR9, DCLK1, 
AKAP12, S100A7, HAS2, FAM25A, PAPL, LOC100131726, DIO3, KLK6, AGPAT9, 
ARC, LY6D, NKD2, PAEP, DIRAS3, ANPEP, SPRR2D, CYB5R2, LCE1F, 
CEACAM1, STC1, HYAL1, SERPINB1, BMP6, AQP5, SPRR1A, FERMT1, TAGLN3, 
CA6, SCNN1D, LCE1C, TMEM45B, CALB2, SOX8, ANGPTL4, ASPRV1, SLC5A1, 
CEACAM6, TNFRSF11B, WNT9A, S100P, EEF1A2, ISG20, TRPV3, PLA2G4E, 
SRMS, PADI1, SH2D2A, GJB4, ADAM8, FAM83A, SULT2B1, CXCL3, CALB1, 
CNFN, EGR3, G0S2, HBEGF, SERPINB2, FOS, LCE1E, ANO1, APOBEC3A, 
KCNN4, LOC100505839, EGR1, RHCG, ODC1, RPSAP52, CYP4F22, EMP1, TGM2, 
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PNMA2, TMEM121, AGR2, SCNN1G, PAQR5, SSTR1, LOXL4, DUSP6, SYTL5, 
S100A1, ZBED2, WNT7B, ROBO4, NGEF, CCNA1, IVL, SOCS1, LIF, KRT18, 
HSPA1A, HSPA1B, HSPA7, DNAJA4, CCL26, CRYAB, BAG3, HSPB8, HSP90AA1, 
HSP90AA4P, DNAJB1, ATF3, OXTR, HSPH1, SH3BGR, DNAJB4, CCL2, ACTBL2, 
HMOX1, ZFAND2A, IL7R, CHAC1, ULBP1, DNAJA1, UBB, GLYATL2, UBC, 
CDRT1, EPSTI1, FAM49A, BST2, LOC100130238, HSPD1, HSPA8, ID4, TNFAIP2, 
MGC16121, DUSP8, MB21D1, DLC1, FILIP1L, SESN2, LAMP3, BEX1, CHORDC1, 
ZNF323, LOC285629, HSPE1, HSP90AA6P, LOC727896, GBP1, CACYBP, IFRD1, 
C21orf7, FERMT3, MORC4, TMEM27, METTL7A, ABHD3, GREM1, CFB, 
CCDC117, LIMCH1, ENGASE, LGR5, DFNB31, LCN10, SLC16A14, DIO2, CYFIP2, 
CLU, ALOXE3, ADM2, IFI44L, NECAB2, ASAP3, COL1A1, ARHGAP24, SLC34A2, 
MARVELD3, ABCB1, LHFPL2, RGS2, CSRP2, HERC5, ZNF761, MICB, FAM26E, 
GDF5, ANGPTL7, FKBP4, C4orf49, SOD2, SLC2A12, STIP1, MITF, TRIM22, GSR, 
BBOX1, DDIT3 
200 Gene RAF Signature 
RAF1, DHRS9, CA6, SPRR2D, PRSS22, S100A7, STC1, IL1RL1, PAEP, BMP6, 
LCE3D, HAS2, CEACAM1, FGFBP2, AGPAT9, SPP1, DIO3, DIRAS3, ISG20, 
TNFRSF11B, LOC100131726, DCLK1, SERPINB1, CRTAM, AQP5, ATP12A, LY6D, 
FERMT1, ASPRV1, SRMS, CEACAM6, CYB5R2, FAM83A, SLC5A1, SERPINB2, 
TMEM45B, KLK6, CALB2, SYTL5, CRHR1, GJB4, CCL24, LY6H, SERPINB3, 
LCE1F, SSTR1, KIAA1199, ENDOU, NTSR1, SCNN1D, PNMA2, EEF1A2, CXCL17, 
EMP1, TMPRSS4, CXCR1, RLBP1, WFDC3, LCE1E, TMCC3, SPRR3, SMOX, 
WNT9A, ADAM8, SHC4, HMGA2, GUCY1B3, CEACAM3, HPSE, RPSAP52, NCF2, 
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SNTB1, TAGLN3, PI3, NAV3, SOCS1, PADI1, PKIB, CD55, GPR110, NOX5, NGEF, 
LBH, FGF1, GAL, S100A4, PLAU, PAPL, SNX9, EDNRA, BPGM, SHF, PLLP, 
IL23A, FIBCD1, PPBP, B3GNT3, C15orf62, TMEM163, RORB, ANPEP, CHST6, 
KCNJ15, GLRX, MALL, RASSF8, APOA1, CCNA1, PITPNC1, IRAK2, SLC26A9, 
TMEM158, CLEC2B, RTKN2, ITGA2, ANO1, ETV5, CLDN10, KCNN4, PLAUR, 
SDR16C5, GABRA2, PGF, TGFA, LOC100505839, PMP22, RAPH1, RASA3, 
LRRC8C, FAM176A, ATG16L1, MCTP1, AKAP12, GDNF, CHRNA9, PI15, HBEGF, 
B3GNT2, MAP1B, ELK3, PTPN22, PTAFR, SPRY4, SH2D2A, STRA6, BMP2, 
KRT18, CARD11, ETV1, ITGB7, WNT7A, TTC9, SLCO4A1, ODC1, CSGALNACT2, 
SLC9A2, LY6K, SREK1IP1, GRB7, ROBO4, ARHGAP25, ZPLD1, FAM100B, DAB2, 
PAQR5, METTL7B, LRAT, SPRY2, SLC1A1, LYPD5, SLC10A6, C14orf49, PRDM8, 
RAC2, PTPRE, HSPA6, HSPA7, DNAJA4, HSPA1A, HSPA1B, TNFAIP2, ACTBL2, 
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